

68904 U.S. PTO



05/14/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No. 1998-028-25 DIV

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Sir: This is a request for filing a

☐ Continuation

application under 37 C.F.R. §1.60,

☒ Divisional

of copending prior application Serial No. 08/510,046, filed on May 31, 1995
of MATTHEW T. SCHOLZ, ROBERT A. SCHERRER, NELDA M. MARECKI,
YEN-LANE CHEN, JOAN K. BARKHAUS (Inventors) for
BIOADHESIVE COMPOSITION AND PATCH (title of invention)

1. "Enclosed is a copy of the latest inventor-signed prior application, including a copy of the oath or Declaration showing the original signature or an indication it was signed. I hereby verify that the papers are a true copy of the latest signed prior application Serial No. 08/510,046, and further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon."
2. ☐ A verified statement to establish Small Entity status under 37 CFR 1.9 and 1.27
☐ is enclosed
☐ was filed in prior application Serial No. _____ and such status is still proper and desired (37 CFR 1.28(a)).
3. ☒ The filing fee is calculated below:

4770 101A



08/855933

11105 U.S. PTO

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY
PRELIMINARY AMENDMENT AND/OR AMENDMENT BELOW

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS	20 - 20 =	-	X \$ 22 =	\$ -
	INDEPENDENT	3 - 3 =	-	X \$ 80 =	\$ -
	MULTIPLE DEPENDENT CLAIMS			+ \$260 =	\$ -
	BASIC FEE				\$ 770.00
	TOTAL OF ABOVE CALCULATIONS=				\$ 770.00
	Reduction by 50% for filing by Small Entity				\$ -
	TOTAL				\$ 770.00

4. ☒ The Commissioner is hereby authorized to charge any fees which may be required for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Account No. 15-0030. A duplicate copy of this sheet is enclosed.
5. ☒ A check in the amount of \$ 770.00 is enclosed.
6. ☒ Cancel Claims (See Preliminary Amendment).
7. ☒ Amend the specification by inserting before the first line the sentence:
--This is a XX Continuation, XX Division, of application Serial No. 08/510,046 filed on May 31, 1995, pending, which is a XX Division of application Serial No. 07/842,222, filed on February 26, 1992, now abandoned, which is a XX Continuation of application Serial No. 07/607,863, filed on November 1, 1990, now abandoned, which is a XX Continuation-In-Part of application Serial No. 07/486,554, filed on February 27, 1990, now abandoned, which is a XX Continuation-In-Part of application Serial No. 07/431,664, filed on November 3, 1989, now abandoned.--
8. ☐ Drawing(s) are enclosed.

9. ☒ Priority of the following application(s) is claimed under 35 U.S.C. 120:

<u>Application No.</u>	<u>Filing Date</u>	<u>Status</u>
08/510,046	May 31, 1995	Pending
07/842,222	February 26, 1992	Abandoned
07/607,863	November 1, 1990	Abandoned
07/486,554	February 27, 1990	Abandoned
07/431,664	November 3, 1989	Abandoned

10. ☒ The prior application is assigned to: Minnesota Mining & Manufacturing, Co., P.O. Box 33427, St. Paul, Minnesota 551330-3427.

11. ☒ The Power of Attorney in the prior application is to one or more of the following: Norman F. Oblon, Reg. No. 24,618; Marvin J. Spivak, Reg. No. 24,913; C. Irvin McClelland, Reg. No. 21,124; Gregory J. Maier, Reg. No. 25,599; Arthur I. Neustadt, Reg. No. 24,854; Richard D. Kelly, Reg. No. 27,757; James D. Hamilton, Reg. No. 28,421; Eckhard H. Kuesters, Reg. No. 28,870; Robert T. Pous, Reg. No. 29,099; Charles L. Gholz, Reg. No. 26,395; Vincent J. Sunderdick, Reg. No. 29,004; William E. Beaumont, Reg. No. 30,996; Steven B. Kelber, Reg. No. 30,073; Robert F. Gnuse, Reg. No. 27,295; Jean-Paul Lavalleye, Reg. No. 31,451; Stephen G. Baxter, Reg. No. 32,884; Martin M. Zoltick, Reg. No. 35,745; Robert W. Hahl, Reg. No. 33,893; Richard L. Treanor, Reg. No. 36,379; Steven P. Weihrouch, Reg. No. 32,829; John T. Goolkasian, Reg. No. 26,142; Marc R. Labgold, Reg. No. 34,651; William J. Healey, Reg. No. 36,160; Richard L. Chinn, Reg. No. 34,305; Steven E. Lipman, Reg. No. 30,011; Carl E. Schlier, Reg. No. 34,426; James J. Kulbaski, Reg. No. 34,648; Catherine B. Richardson, Reg. No. 39,007; Richard A. Neifeld, Reg. No. 35,299; J. Derek Mason, Reg. No. 35,270; and Jacques M. Dulin, Reg. No. 24,067, all of OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C., Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202.


- a. ☐ The power appears in the original papers of the prior application.
- b. ☒ Since the power does not appear in the original papers, a copy of the powers (2) in the prior application is enclosed.

c. ☐ Recognize as Associate Attorney and address all future communication to:

12. ☒ Preliminary Amendment is enclosed.
13. ☒ Also enclosed: White Advance Serial No. Card;
Copy: Oath, Power of Attorney, and Petition, (executed, 4 pages)

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Charles L. Gholz
Attorney of Record
Registration No. 26,395

Alton D. Rollins
Registration No. 34,083

Fourth Floor
1755 Jefferson Davis Highway
Arlington, Virginia 22202
(703) 413-3000
(703) 413-2220 (fax)

1998-028-25 DIV of
1998/027/25SD



IN RE APPLICATION OF :

MATTHEW T. SCHOLZ, :
ROBERT A. SCHERRER, : GROUP ART UNIT: 1502
NELDA M. MARECKI : (anticipated)
YEN-LANE CHEN AND :
JOAN K. BARKHAUS :

SERIAL NO: Divisional of : EXAMINER: P. KULKOSKY
08/510,046 : (anticipated)

FILED: Herewith :

FOR: BIOADHESIVE COMPOSITION
AND PATCH

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Please enter the following amendments prior to
examination.

IN THE SPECIFICATION

Please cancel the cross reference to related applications
appearing at page 1, lines 7 and 8 and insert the following
paragraph:

--This application is a divisional of application serial
no. 08/510,046, filed May 31, 1995, which is a division of
application serial no. 07/842,222, filed February 26, 1992,
now abandoned, which is a continuation of application serial
no. 07/607,863, filed November 01, 1990, now abandoned, which
is a continuation-in-part of application serial no.
07/486,554, filed February 27, 1990, now abandoned, which is a

continuation-in-part of application serial no. 07/431,664,
filed November 03, 1989, now abandoned.--

IN THE CLAIMS

Please cancel Claims 1-124 and add the following claims
under 37 CFR 1.607(a)(4).

--125. A method for mucosally administering a
macromolecular drug to the oral cavity comprising applying to
the oral cavity mucosa a system comprising an inner
drug/enhancer/polymer layer having one surface adapted to
contact the mucosal tissue of the oral cavity and adhere
thereto when wet and an opposing surface in contact with and
adhering to an overlying inert layer, said inner layer
containing an effective amount of a bile salt enhancer, from
about 29 to 80% by weight of a hydrophilic polymer, and an
effective amount of a macromolecular drug.

126. A method according to claim 125 wherein said bile
salt enhancer is selected from the group consisting of sodium
glycocholate, sodium taurocholate, and sodium tauro-24,25-
dihydrofusidate.

127. A method according to claim 126 wherein said
macromolecular drug is a member selected from the group
consisting of polysaccharides, polypeptides, and proteins.

128. A method according to claim 127, wherein said
hydrophilic polymer is a member selected from the group
consisting of acrylic acid polymers, maleic acid polymers,

itaconic acid polymers, citraconic acid polymers, methacrylic acid polymers; copolymers of a member selected from the group consisting of acrylic acid and methacrylic acid with a member selected from the group consisting of methyl vinyl ether and lower alkyl methacrylates; and acrylic acid polymers cross-linked with a polyalkenyl ether selected from the group consisting of allyl ether of sucrose and allyl ether of pentaerythritol.

129. A method according to claim 128 wherein the macromolecular drug is a polysaccharide.

130. A method according to claim 129 wherein the polysaccharide is heparin.

131. A method according to claim 128 in the form of a film patch wherein said inert layer is a polymer which is nonadhesive to mucosal tissues and is substantially impermeable to the bile salt enhancer or the drug.

132. A method for mucosally administering a macromolecular drug to the oral cavity comprising applying to an oral cavity mucosa a system comprising an inner drug/enhancer/polymer layer having one surface adapted to contact the mucosal tissue of the oral cavity and adhere thereto when wet and an opposing surface in contact with and adhering to an overlying inert layer, said inner layer containing from 0% to an effective amount by weight of a bile salt enhancer, about 29 to 80% by weight of a hydrophilic polymer, and an effective amount of a macromolecular drug.

133. A method according to claim 132 wherein the bile salt enhancer is sodium taurocholate.

134. A method according to claim 133 wherein said macromolecular drug is a member selected from the group consisting of polysaccharides, polypeptides, and proteins.

135. A method according to claim 134 wherein said hydrophilic polymer is a member selected from the group consisting of acrylic acid polymers, methacrylic acid polymers, copolymers of acrylic acid with a member selected from the group consisting of methyl vinyl ether and lower alkyl methacrylates, methacrylic acid copolymers with a member selected from the group consisting of methyl vinyl ether and lower alkyl methacrylates, and polymers of acrylic acid cross-linked with a polyalkenyl polyether.

136. A method according to claim 135 wherein the macromolecular drug is a polysaccharide.

137. A method according to claim 136 wherein the polysaccharide is heparin.

138. A method according to claim 135 in the form of a film patch wherein said inert layer is a polymer which is nonadhesive to mucosal tissues and is substantially impermeable to the bile salt enhancer or drug.

139. A method for mucosally administering a macromolecular drug to the oral cavity comprising applying to an oral cavity mucosa a system comprising an inner drug/polymer layer having one surface adapted to contact the

mucosal tissue of the oral cavity and adhere thereto when wet and an opposing surface in contact with and adhering to an overlying inert layer, said inner layer containing from about 29 to 80% by weight of a hydrophilic polymer and an effective amount of a macromolecular drug.

140. A method according to claim 139 wherein the macromolecular drug is a member selected from the group consisting of polysaccharides, peptides, and proteins.

141. A method according to claim 140 wherein said hydrophilic polymer is a member selected from the group consisting of polyacrylic acid, polymethacrylic acid, copolymers of acrylic acid with a member selected from the group consisting of methyl vinyl ether and lower alkyl methacrylates, copolymers of methacrylic acid with a member selected from the group consisting of methylvinyl ether and alkyl methacrylates, and polymers of acrylic acid cross-linked with a polyalkenyl polyether.

142. A method according to claim 141 wherein the macromolecular drug is a polysaccharide.


143. A method according to claim 142 wherein the polysaccharide is heparin.

144. A method according to claim 139 wherein the macromolecular drug is heparin and the hydrophilic polymer is a linear polyacrylic acid resin cross-linked with a member selected from the group consisting of an allyl ether of sucrose and an allyl ether of pentaerythritol.--

REMARKS

The foregoing claims 125-144 have been copied from a patent for purposes of interference. The 37 CFR 1.607 request filed herewith identifies the patent with which an interference is sought and demonstrates 35 USC 112 support in this application for the new claims.

Respectfully submitted,



Charles L. Gholz
Registration No. 26,395
Alton D. Rollins
Registration No. 34,083
OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Fourth Floor
1755 Jefferson Davis Highway
Arlington, Virginia 22202
Tel: (703) 413-3000
Fax: (703) 413-2220

I:\ADR\19980027.pr
/ml

87/486,554
COPY

PATENT

Docket Number: 43852USA4C

BIOADHESIVE COMPOSITION AND PATCH

5

CROSS REFERENCE TO RELATED APPLICATION

10 This application is a continuation-in-part of
U.S. Serial No. 07/486,554, filed February 27, 1990, which
is a continuation-in-part of U.S. Serial No. 07/431,664,
filed on November 3, 1989.

BACKGROUND OF THE INVENTION

15 Field of the Invention

This invention relates to mucosal adhesives. In
another aspect this invention relates to compositions that
adhere to oral mucosa. In yet another aspect this
invention relates to methods of transmucosal drug
20 delivery.

Description of the Related Art

25 Buccal tablets and like devices are known and
disclosed for example in U.S. Pat. Nos. 4,740,365 and
4,764,378. These devices adhere to mucosal surfaces and
dissolve or otherwise disintegrate over time, thus
delivering drug into the mouth of the patient in a
sustained fashion. It is also known that delivery of
drugs across the oral mucosa avoids hepatic first-pass
30 inactivation, inactivation by gastro-intestinal fluids,
and other modes of inactivation characteristic of oral
drug ingestion. Sustained release adhesive bandages,
patches, and the like that contain drugs and adhere to
mucosal surfaces are known to the art. Polyacrylic acids
35 and polyisobutylenes have been disclosed as components of
such adhesives. For example, U.S. Pat. No. 3,339,546

(Chen) discloses a bandage that is said to adhere to moist surfaces of the oral cavity and comprises a medicament and a hydrocolloid incorporated in a natural or synthetic gum-like substance. Carboxypolymethylene (i.e., polyacrylic acid) is among the hydrocolloids disclosed, and polyisobutylene is among the gum-like substances disclosed.

U.S. Pat. No. 4,615,697 (Robinson) discloses a composition including a bioadhesive and a treating agent. The bioadhesive is a water-swellaable but water insoluble, fibrous, crosslinked, carboxy-functional polymer containing (a) a plurality of repeating units of which at least about 80% contain at least 1 carboxy functionality, and (b) about 0.05 to about 1.5% of a cross-linking agent substantially free from polyalkenyl polyether. The specifically excluded type of crosslinker is said to be the type used in CARBOPOLTM 934 resin (commercially available from B. F. Goodrich, Specialty Chemicals and Polymers Division, Cleveland, OH). CARBOPOLTM 934 resin is said to be water soluble and therefore undesirable as a bioadhesive in the Robinson composition.

U.S. Pat. No. 4,253,460 (Chen et al.) discloses an adhesive composition consisting of a mixture of a hydrocolloid gum, a pressure sensitive adhesive, and a cohesive strengthening agent. The pressure sensitive adhesive component can be a mixture of three to five parts of a polyisobutylene with a viscosity average molecular weight of about 36,000 to about 53,000 and one part of an elastomer such as a polyisobutylene with a viscosity average molecular weight of about 1,150,000 to about 1,600,000.

U.S. Pat. No. 4,740,365 (Yukimatsu et al.) discloses a sustained-release preparation comprising an active ingredient and a mixture of two polymer components, the first of which comprises one or more polymers selected from polyacrylic acid and a pharmaceutically acceptable salt thereof, and the second being selected from the group

consisting of polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid, and a pharmaceutically acceptable salt of alginic acid. CARBOPOLTM resins are among the polymers said to be suitable members of the first-mentioned class of polymers.

U.S. Pat. No. 4,772,470 (Inoue, et al.) discloses an oral bandage comprising a mixture of a polyacrylic acid and a vinyl acetate polymer in a compatible state. This bandage is said to exhibit strong adhesion of long duration when applied to oral mucosa or teeth.

SUMMARY OF THE INVENTION

This invention provides a bioadhesive composition that comprises:

- 1) a particulate polymeric resin with an average particle size of less than or equal to about 100 μ m and comprising at least about 55% by weight of carboxylic acid moieties based on the total weight of the polymeric resin;
 - 2) from about 20 parts to about 250 parts by weight of a hydrophobic elastomeric component, based on 100 parts by weight of the resin; and
 - 3) an amount of a drug effective to provide a desired therapeutic result,
- wherein the resin and the drug are dispersed substantially throughout the elastomeric component, and which composition contains less than about 10% water by weight based on the weight of the polymeric resin, exhibits substantially no instantaneous adhesion to dry skin, and adheres to a mucosal surface.

A bioadhesive composition of this invention exhibits good adherence to human oral mucosa. In particular embodiments, this invention provides a bioadhesive composition as described above that exhibits a duration of adhesion to human oral mucosa of at least about 6 hours when tested according to the Test Method

described in detail below. Also, the drug is released in sustained fashion over a prolonged period to a mucosal surface for, for example, local or systemic treatment.

In a preferred embodiment when systemic
5 treatment is desired, the bioadhesive composition has a backing such as a flexible film applied to it.

Further, in yet another preferred embodiment the resin is covalently crosslinked with about 0.75% to about 2% by weight, based on the total weight of the resin, of a
10 polyalkenyl polyether. The preferred resin can also be partially neutralized (e.g., up to about 30%) with a base of mono, di- or trivalent metal, or with a polyamine.

This invention also provides therapeutic methods. One such method is a method of achieving and/or
15 maintaining a therapeutically effective blood level of a drug in a mammal, comprising the steps of:

a) adhering a composition of the invention to a mucosal surface of a mammal; and

b) allowing the composition to remain adhered
20 for a time sufficient to release the drug such that a therapeutically effective blood level of drug is achieved and/or maintained.

Another such method is a method of delivering a drug to a mucosal surface of a mammal or to the vicinity
25 of a mucosal surface of a mammal to provide a therapeutic effect on or in the vicinity of the mucosal surface, which method comprises the steps of:

a) adhering a composition of the invention to the mucosal surface;

b) allowing the composition to remain adhered
30 for a time sufficient to release the drug to the mucosal surface or to the vicinity of the mucosal surface to provide the desired therapeutic effect.

A composition of the invention can be used to
35 administer drugs systemically (e.g., across the oral or vaginal mucosa or other mucosal surfaces) or locally (e.g., to the oral or vaginal cavity). A composition of

the invention exhibits sustained delivery of basic, acidic, and neutral drugs, and salts thereof and allows the delivery rate to be tailored as desired. In the case of delivery of a drug across the oral mucosa, a composition of the invention can also minimize the loss of a drug to the gastro-intestinal tract. A composition of the invention is also soft and conformable such that it can be worn comfortably by the user.

Detailed Description of the Invention

The polymeric resin component of a composition of the invention comprises at least about 55% by weight of carboxylic acid moieties based on the total weight of the resin. Suitable carboxylic acid-containing monomers include acrylic acid, maleic acid, itaconic acid, citraconic acid, methacrylic acid, and the like, and combinations thereof. Acrylic acid is preferred. The polymeric resin can also comprise minor amounts (e.g., less than about 20 percent by weight based on the total weight of all monomers in the polymer) of comonomers that are polymerizable with the carboxylic acid-containing monomer, such as methyl vinyl ether, lower alkyl (meth) acrylates, and the like.

Linear polyacrylic acid resins with a molecular weight between about 400,000 and about 5,000,000 have been found to be suitable for use in a composition of the invention. More preferred, however, are crosslinked resins. Most preferred resins include those comprising polyacrylic acid with a molecular weight between about 750,000 and about 4,000,000, preferably about 2,000,000 to about 4,000,000, and more preferably about 3,000,000, crosslinked with about 0.75% to about 2% by weight, based on the total weight of the resin, of a polyalkenyl polyether such as an allyl ether of sucrose or an allyl ether of pentaerythritol. Particularly preferred resins of this type include the resins available under the trade designation CARBOPOLTM resin (e.g., CARBOPOLTM resins 910,

934, 934P, 941, 951, and 1342 from B.F. Goodrich Co., Specialty Polymers and Chemical Division, Cleveland, OH). CARBOPOLTM 934P resin is most preferred, as it is generally recognized as acceptable for pharmaceutical applications. Another suitable resin is "polycarbophil", a material commercially available from A. H. Robins Co., Richmond, Virginia, and described in USP XX as a polyacrylic acid crosslinked with divinylglycol.

A polyacrylic acid resin or a crosslinked resin such as those enumerated above can be partially neutralized by a base of an alkali metal, or by a base of a divalent or trivalent metal (e.g., Zn^{+2} , Ca^{+2} , Mg^{+2} , or Al^{+3}). Basic polyamines such as EudragitTME (a copolymer of dimethylaminoethyl methacrylate and neutral methacrylates, available from Rohm Pharma, Weiterstadt, Germany) are also suitable for use in neutralizing a resin. In such a resin, up to about 30% of the carboxylic acid moieties in the resin can be neutralized by a base. Preferred bases include $Al(OH)_3$ and $Ca(OH)_2$.

The particle size of the resin affects the adhesion of a composition of the invention to mucosal surfaces, the rate of disintegration, and the rate at which a composition releases drug. Proper particle size affords a composition with sufficient surface area of the resin available to provide good adhesion, but not so much that the composition rapidly disintegrates when placed on a mucosal surface, e.g., in the oral cavity. Average particle size can be up to about 100 μm . It is preferred that the resin have an average particle size of between about 1 μm and about 80 μm , more preferably between about 1 μm and about 30 μm , and most preferably between about 2 μm and about 10 μm .

It is desirable to keep the level of moisture low in a bioadhesive composition of the invention. A bioadhesive composition has a water content of less than about 10% by weight, preferably less than about 6%, more preferably less than about 4% by weight, and most

preferably less than about 2% by weight based on the total weight of the resin. In order for the composition to have the requisite low water content the resin, prior to incorporation in the composition, is preferably dried to the desired level and protected from ambient moisture. Once the resin is incorporated in a composition of the invention, ambient moisture is no longer generally of concern, as the resin, which is generally hygroscopic, is protected from ambient moisture by the hydrophobic elastomeric component. A composition can be stored for at least several months at ambient humidity without adversely affecting its adhesive properties.

By itself, a polymeric resin as described above generally possesses insufficient structural integrity. Such acidic resins can also be irritating to mucosal tissue. Further, a resin alone provides no means of controlled hydration and sustained release of drug. To remedy these deficiencies, the resin is substantially dispersed throughout a hydrophobic elastomeric component.

The relative amounts of the polymeric resin and the hydrophobic elastomeric component can affect both the duration of adhesion and the drug release properties of a composition of the invention. Generally a composition of the invention comprises about 20 parts to about 250 parts, preferably about 20 parts to about 150 parts, and most preferably 25 to about 75 parts by weight of a hydrophobic elastomeric component, based on 100 parts by weight of the resin.

Suitable elastomeric components preferably are soft such that the ultimate composition can be worn without significant discomfort to the user. Further, they are such that a composition of the invention does not exhibit excessive cold-flow when stored at room temperature. The hydrophobic elastomeric component preferably has a surface energy of less than about 40 dyne/cm and more preferably has a surface energy of less than about 30 dyne/cm.

Examples of materials suitable for use in an elastomeric component include: hydrocarbons such as block styrene-butadiene-styrene copolymers and block styrene-isoprene-styrene copolymers, such as those available from Shell Chemical Co. as KratonTM rubbers, 5 polyolefins such as polyisobutylenes, polybutadienes, butyl rubber (a copolymer of isobutylene and isoprene), and isoprene rubbers, e.g., polyisoprene (such as that available as LIR-50 polyisoprene from Arakawa Chemical Co., Chicago, IL and NATSYNTM polyisoprene from Goodyear, 10 Akron, OH); functionalized polyolefins such as functional polyisoprenes, e.g., carboxy-functional polyisoprenes (such as that available as LIR-410 polyisoprene, also from Arakawa) and hydroxy-functional polyiso-prenes (such as that available as LIR-506 polyisoprene, Arakawa); and 15 mixtures and blends of two or more of the foregoing.

Another class of material suitable for use in an elastomeric component includes acrylate elastomers. Suitable acrylate elastomers include polymers and 20 copolymers comprising at least about 60 percent by weight based on the total weight of all monomers in the polymer of a hydrophobic monomeric acrylic or methacrylic acid ester of an alkyl alcohol, the alkyl alcohol containing 4 to 10 carbon atoms. Some such elastomers are disclosed in U.S. Pat. No. 4,751,087 (Wick) the disclosure of which is 25 incorporated herein by reference. Particularly suitable are those acrylate copolymers containing A and B Monomers as follows: Monomer A is a hydrophobic monomeric acrylic or methacrylic acid ester of an alkyl alcohol, the alkyl alcohol containing 4 to 10 carbon atoms, preferably 8 30 carbon atoms. Examples of suitable A Monomers are n-butyl, n-pentyl, n-hexyl, isoheptyl, n-nonyl, n-decyl, isohexyl, isooctyl, 2-ethyloctyl, and 2-ethylhexyl acrylates. The most preferred A Monomer is isooctyl acrylate. Monomer B is a reinforcing monomer selected 35 from the group consisting of acrylic acid; methacrylic

acid; alkyl acrylates and methacrylates containing 1 to 3 carbon atoms in the alkyl group; acrylamide; methacrylamide; and lower alkyl-substituted acrylamides (i.e., the alkyl group containing 1 to 4 carbon atoms) such as tertiary-butyl acrylamide. The most preferred B Monomer is acrylamide. In such an elastomer, the A Monomer is preferably present in an amount by weight of about 80 percent to about 98 percent, and the B Monomer is preferably present in an amount by weight of about 2 to about 20 percent of the total weight of the monomers in the copolymer. While such acrylate copolymers per se are pressure-sensitive adhesives, when they are incorporated into a composition of the invention, the composition exhibits substantially no instantaneous adhesion to dry skin.

Hydrocarbons are the most preferred materials for use in an elastomeric component. Preferred hydrocarbon elastomeric components, particularly when the composition is prepared by the solvent casting method set forth in detail below, include polyisobutylene mixtures comprising, based on the total weight of the polyisobutylene mixture, from about 5% to about 50% preferably about 15% to about 25%, and most preferably about 20% weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2,500,000, preferably about 1,250,000, and from about 50% to about 95%, preferably about 75% to about 85%, and most preferably about 80%, by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000, preferably about 53,000. Particularly preferred is an elastomeric component made by the solvent-casting method and consisting of about 80% by weight of VISTANEXTM LM-MH polyisobutylene and about 20% by weight of VISTANEXTM L-100 polyisobutylene.

In contrast to solvent-casting processes, the milling process (set forth in detail below) can reduce substantially the average molecular weight of the polymers

that are used in the process. For example, some preferred polyisobutylene elastomers in embodiments made by the milling process are made from the preferred polymers enumerated above but they have molecular weights somewhat lower than the molecular weight ranges set forth above.

5 Another preferred elastomeric component when the composition is prepared by the milling method is a polyisobutylene mixture made from about 60 to about 100% by weight a polyisobutylene with a viscosity average molecular weight of about 750,000 to about 1,500,000 most
10 preferably about 900,000, and 0% to about 40% of a polyisobutylene with a viscosity average molecular weight of about 40,000 to about 100,000, most preferably about 53,000.

15 Further preferred elastomeric components, particularly for use when the milling method is employed, comprise polyisoprene, polybutadiene, or a mixture thereof. Polyisoprenes having molecular weights of about 500,000 to about 1,200,000, and mixtures thereof, are
20 suitable. Polybutadienes having a molecular weight of about 100,000 to about 500,000, and mixtures thereof, are suitable. Mixtures of such polyisoprenes and polybutadienes are also suitable. A particularly preferred elastomeric component when the composition is prepared by
25 the milling method is made from a mixture of about 20 to about 80 percent by weight, preferably about 50 percent by weight, of a polybutadiene having a molecular weight of about 375,000 and about 20 to about 80 percent by weight, preferably about 50 percent by weight, of a polyisoprene
30 having a molecular weight of about 760,000.

Exemplary specific polyisobutylenes suitable for use in the above-described elastomeric components include those commercially available from Exxon Chemical Co., Houston TX, under the trade designation VISTANEXTM
35 polyisobutylene and those commercially available from BASF under the trade designation OPPANOLTM polyisobutylene. Preferred polyisobutylenes include VISTANEXTM LM-MH polyisobutylene (viscosity average molecular weight about 53,000), VISTANEXTM L-80 polyisobutylene (viscosity

average molecular weight about 900,000), and VISTANEXTM L-100 polyisobutylene (viscosity average molecular weight about 1,250,000). Exemplary specific polyisoprenes suitable for use include those commercially available from Goodyear, Akron, OH, under the trade designation NATSYNTM 2210 polyisoprene (weight average molecular weight about 760,000) and NATSYNTM 2205 polyisoprene (weight average molecular weight about 955,000). Exemplary specific polybutadienes suitable for use include those commercially available from Polysar, Akron, OH under the trade designation TAKTENETM 1202 polybutadiene (weight average molecular weight about 375,000).

For purposes of the instant specification and claims, the term viscosity average molecular weight means Flory molecular weight as determined by the method set forth in "Food Chemicals Codex", 3rd Ed. page 469, 1981. National Academy Press, incorporated herein by references.

An elastomeric component can also comprise a plasticizer such as mineral oil, silicone oil, corn oil, and the like. A particularly preferred elastomeric component of this type is a mixture comprising mineral oil and linear styrene-isoprene-styrene block copolymer such as that commercially available from Shell Chemical, Houston, TX, under the trade designation KRATONTM D 1107 rubber. It is preferred that an elastomeric component of this type comprise from about 20 percent to about 40 percent, more preferably about 33 percent, by weight of mineral oil and correspondingly from about 60 percent to about 80 percent, more preferably about 67 percent, by weight of the block copolymer.

The resin can be substantially uniformly dispersed throughout the elastomeric component, or it can be present in any suitable gradient, e.g., a gradient wherein there is a substantially higher concentration of the resin nearer the surface that is intended to be

adhered to a mucosal surface. The term "gradient" as used herein represents a continuous or discontinuous variation in concentration across the cross-sectional thickness of a composition.

5 A bioadhesive composition of the invention also comprises a drug. Drugs that can be delivered include those useful for the local treatment of the mouth or throat, or the vaginal cavity, in addition to those useful for systemic treatment via delivery through mucosal
10 tissue. They include antiinflammatory drugs, both steroidal (e.g., hydrocortisone, prednisolone, triamcinolone) and nonsteroidal (e.g., naproxen, piroxicam); bacteriostatic agents (e.g., chlorhexidine, hexylresorcinol); antibacterials (e.g., penicillins such
15 as penicillin V, cephalosporins such as cephalexin, erythromycin, tetracycline, gentamycin, sulfathiazole, nitrofurantoin, and quinolones such as norfloxacin, flumequine, and ibafloxacin); antiprotazoals (e.g., metronidazole); antifungals (e.g., nystatin); coronary vasodilators (e.g., nitroglycerin); calcium channel
20 blockers (e.g., nifedipine, diltiazem); bronchodilators (e.g., theophylline, pirbuterol, salmeterol, isoproterenol); enzyme inhibitors such as collagenase inhibitors, protease inhibitors, elastase inhibitors, lipoxxygenase inhibitors (e.g., A64077), and angiotensin
25 converting enzyme inhibitors (e.g., captopril, lisinopril); other antihypertensives (e.g., propranolol); leukotriene antagonists (e.g., ICI204,219); anti-ulceratives such as H2 antagonists; steroidal
30 hormones (e.g., progesterone, testosterone, estradiol); antivirals and/or immunomodulators (e.g., 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine, 1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinoline-4-amine, and other compounds disclosed in U.S. Pat. No.
35 4,689,338, incorporated herein by reference, acyclovir); local anesthetics (e.g., benzocaine, propofol); cardiotonics (e.g., digitalis, digoxin); antitussives

(e.g., codeine, dextromethorphan); antihistamines (e.g., diphenhydramine, chlorpheniramine, terfenadine); narcotic analgesics (e.g., morphine, fentanyl); peptide hormones (e.g., human or animal growth hormones, LHRH);

5 cardioactive products such as atriopeptides; proteinaceous products (e.g., insulin); enzymes (e.g., anti-plaque enzymes, lysozyme, dextranase); antinauseants (e.g., scopolomine); anticonvulsants (e.g., carbamazine); immunosuppressives (e.g., cyclosporine);

10 psychotherapeutics (e.g., diazepam); sedatives (e.g., phenobarbital); anticoagulants (e.g., heparin); analgesics (e.g., acetaminophen); antimigraine agents (e.g., ergotamine, melatonin, sumatripan); antiarrhythmic agents (e.g., flecainide); antiemetics (e.g., metaclopramide, ondansetron); anticancer agents (e.g., methotrexate);

15 neurologic agents such as anxiolytic drugs; hemostatics; anti-obesity agents; and the like, as well as pharmaceutically acceptable salts and esters thereof. Preferred drugs include digoxin, heparin, hydromorphone, morphine, melatonin, buprenorphine, and pharmaceutically

20 acceptable salts thereof.

A drug is preferably incorporated neat into a composition of the invention. The drug is preferably present in an effective amount, which will depend upon the particular drug used, the intended therapy, and the

25 desired duration of use of a particular individual application of the composition containing the drug. Practical limitations on the amount of drug incorporated in a composition are that amount above which the composition begins to lose adhesion to a mucosal surface,

30 and that amount below which a therapeutically effective blood level of drug cannot be achieved and/or maintained. Generally, the preferred range is from about 0.1% to about 25% by weight based on the total weight of the bioadhesive

composition. Preferably, the drug will be capable of release from the composition in a sustained fashion over a prolonged period (i.e., at least about 6 hours and preferably at least about 12 hours).

5 The drug is generally dispersed throughout the elastomeric component. The drug can be substantially uniformly dispersed, or it can be distributed in any suitable gradient, e.g., a gradient wherein drug
10 concentration is greater nearer the surface that is intended to be adhered to a mucosal surface, or a gradient wherein drug concentration is lower nearer the surface that is intended to be adhered to a mucosal surface, in order to achieve the desired blood-level profile.

 A composition can contain other ingredients, for
15 example excipients such as flavorings or flavor-masking agents, dyes, penetration enhancers, water-soluble or water-swellaible fibrous reinforcers, and the like under circumstances and in amounts easily determined by those skilled in the art. Penetration enhancers have particular
20 utility when used with drugs such as peptides and proteins. Suitable penetration enhancers include anionic surfactants (e.g., sodium lauryl sulfate); cationic surfactants (e.g., cetylpyridinium chloride); nonionic surfactants (e.g., polysorbate 80, polyoxeyethylene
25 9-lauryl ether, glyceryl monolaurate); lipids (e.g., oleic acid); bile salts (e.g., sodium glycocholate, sodium taurocholate); and related compounds (e.g., sodium tauro-24,25-dihydrofusidate). Like the drug discussed above, such ingredients can be dispersed substantially
30 uniformly in the composition or dispersed in any suitable gradient therein.

 A resin useful in a composition of this
invention can be prepared using conventional procedures and conventional laboratory equipment. For example, such
35 resins can be prepared from acrylic acid and the appropriate crosslinkers by methods well known to those skilled in the art, and disclosed for example in U.S. Pat.

No. 2,798,053 (Brown). A commercially available polyacrylic acid resin or a commercially available particulate resin such as the CARBOPOLTM resins discussed above can be used as received if it is available in an appropriate particle size and with a suitably low water content.

Conventional drying methods, preferably using temperatures less than about 95°C, and more preferably less than about 50°C, can be used to dry a resin to the desired degree, e.g., less than about 2% water content. Further, if it is desired to increase or decrease the particle size, a resin can be wet-granulated by first wetting and stirring with a polar solvent (e.g., isopropyl alcohol), drying to the desired degree (e.g., in a tray oven), and then milling to a powder of the desired size. Particle size can also be adjusted by other conventional techniques, with the caveat that substantial degradation of the resin is to be avoided.

To prepare a neutralized resin as discussed above, a particulate polyacrylic acid resin or a particulate covalently crosslinked resin can be suspended by vigorously stirring in a water-soluble solvent (e.g., ethanol, isopropyl alcohol, or methanol). To this suspension, an aqueous solution containing the polyamine or the desired base of a metal can be added. Upon vigorous agitation (e.g., shaking overnight in a conventional laboratory shaker) a homogeneous mixture containing the neutralized resin obtains. Drying this mixture, for example by spray drying, affords a free-flowing powder. With high concentrations of base, a spray drying process can become more time consuming than desired, in which case a wet-granulation process might be preferred. In such a process, the polyacrylic acid resin and the base can first be mixed as solids, then moistened with a polar solvent (e.g., isopropyl alcohol) and stirred. Under such conditions, it is possible that significant neutralization does not occur. However, when

the resulting resin is incorporated into a composition of the invention as described below, and the composition is placed on a moist surface such as a mucosal surface, it is possible that further neutralization occurs in situ. For the purposes of the instant specification and claims, a material so made is termed a neutralized resin prior to presumed further in situ neutralization. In any case, the resulting mixture can then be dried to the desired degree and milled using conventional apparatus to form a powder of the desired particle size.

A suitable resin can then be formulated into a composition of the invention by a solvent-casting method that involves dispersing the resin, e.g., with stirring, in a solution of an elastomeric component in a volatile organic solvent, such as hexane or toluene, to form a resin/elastomeric component/solvent mixture. A drug and any excipient or other ingredient can be incorporated by first adding it and then the resin, or vice-versa, to a solution of the elastomeric component in a volatile organic solvent. Alternatively, a drug and any excipient or other ingredient can be incorporated by first adsorbing it on the resin or on an inert support such as silica, absorbing it into the resin, or ionically binding it to the resin. The composition can then be made into a sheet. This can be done by coating (e.g., using a knife coater) a suitable release liner with a uniform thickness of a resin/elastomeric component/solvent mixture containing the drug and any excipient or other ingredient and allowing the solvent to be removed without substantial foaming or bubbling caused by solvent release, e.g., by evaporation in air or by drying methods well known to those skilled in the art.

As an alternative that avoids the use of added solvents, the components of a composition can be milled together neat using mill such as a conventional rubber mill (e.g., a two-roll mill). If the elastomeric component comprises more than one ingredient, these

ingredients can be milled together first to form a substantially homogeneous elastomeric component. The polymeric resin and the drug and any excipient or other ingredients can then be milled with the substantially homogeneous elastomeric component in order to form a substantially homogeneous composition of the invention. In some cases it is necessary to heat or cool the rolls in order to assure good mixing and in order to facilitate removal of the composition from the rolls. The drug and any excipient or other ingredients can be added neat to the polymeric resin prior to milling. Alternatively, they can be adsorbed on the resin, adsorbed on an inert support such as silica, absorbed into the resin, or ionically bound to the resin by conventional methods prior to milling. The composition can then be made into a sheet by, for example, pressing between two sheets of release liner in a heated platen press at a pressure of about 35,000 to about 175,000 KPa and at a temperature of about 50°C. The milling method is particularly amenable to the preparation of compositions wherein the resin and/or the drug is distributed throughout the composition in a suitable gradient as described above.

The preferred thickness of the final dry sheet of composition (irrespective of the method of preparation) is from about 0.5 mm to about 5 mm, more preferably from about 1 mm to about 3 mm. Gradient distribution can be carried out by preparing two or more sheets of differing composition and optionally differing thickness (e.g., in the range from about 0.20mm to about 1mm) and laminating them together, e.g., between two sheets of release liner in a heated platen press to produce a composition with the desired gradient. Shims can be used to control the final thickness.

If desired, additional polymeric resin can be spread substantially uniformly on one surface of a sheet of a composition. The composition can then be pressed between two sheets of release liner in order to embed the additional polymeric resin into the composition.

Suitable release liners for use in the above-described methods of preparation include conventional release liners comprising a known sheet material, such as a polyester web, a polyethylene web, or a polystyrene web, or polyethylene-coated paper, coated with a suitable silicone-type coating such as Daubert 164-Z (commercially available from Daubert Co., Elmhurst, IL).

If desired, a backing material can then be applied to the composition using methods well known to those skilled in the art. The backing material is preferably a flexible film that prevents bulk fluid flow and is inert to the ingredients of the composition. In the case of a composition that contains a drug intended to be delivered across a membrane such as a mucosal surface and intended to have systemic action, the backing is preferably substantially resistant to the migration of the drug therethrough. In the case of a composition that contains a drug intended to be delivered, e.g., to the oral cavity or the vaginal cavity and/or intended to have local action, the backing can be permeable to the agent to be delivered and can be permeable to saliva as well. The backing material can be any of the conventional materials used as backing for tapes or dressings, such as polyethylene, polypropylene, ethylene-vinyl acetate copolymer, ethylene propylene diene copolymer, polyurethane, rayon, and the like. Non-woven materials such as polyesters, polyolefins, and polyamides can also be used. Also, a layer of a hydrophobic elastomer such as polyisobutylene can function as a backing. Preferred backing materials include an acrylate pressure-sensitive adhesive coated polyurethane film such as TEGADERMTM -brand surgical dressing (commercially available from the 3M Company, St. Paul, MN).

A composition with a backing applied thereto can be made into a patch with a backing by die-cutting individual patches from the sheet. Alternatively, a patch with no backing can be prepared by die-cutting individual patches from a coated release liner prepared by the solvent method set forth above or by die-cutting from a sheet of bioadhesive composition prepared by pressing between two sheets of release liner. A patch can be of any suitable size and shape, e.g., a 1 cm² circular disk.

Particular embodiments of the invention use no backing or a backing that is substantially permeable to the bodily fluid with which the composition is in contact (e.g., saliva). In such embodiments, it is preferred that the composition exhibit substantially no disintegration over the time period during which the composition is intended to remain adhered to the mucosal surface. This provides for sustained release of the drug over a prolonged period of time.

Other particular embodiments of the invention use a backing that is substantially impermeable to the bodily fluid with which the composition is in contact. In such embodiments, the backing further protects the composition from substantial disintegration over the time period during which the composition is intended to remain adhered to the mucosal surface. However, even in such embodiments a lack of substantial disintegration of the bioadhesive composition itself can serve to optimize the delivery of a drug to the mucosal surface (as opposed to delivery of the drug to the vicinity of the mucosal surface, e.g., to the oral cavity).

"Substantially no disintegration" as used herein means that a bioadhesive composition is resistant to disintegration such that, when the composition having no backing attached thereto is adhered in the oral cavity and tested as set forth in the Test Method below, the composition covers at least about 50% of the area after it is adhered for a designated period of time as is covered by the composition initially.

While compositions of the invention adhere to mucosal surfaces, they exhibit substantially no instantaneous adhesion to dry skin. A composition or a patch of the invention can therefore be handled by a patient without undue concern that the composition or patch will have its mucosal adhesive properties compromised by adhering to the skin or to another dry surface prior to placement on the mucosa.

A composition of the invention or a patch made from a composition of the invention can be applied to a mucosal surface, such as the oral mucosa, e.g., the buccal mucosa or gingival mucosa, of a mammal and replaced as desired (e.g., as is necessary or as is convenient to the user) with a fresh patch, e.g., to maintain a therapeutically effective blood level of a drug. The opposing surfaces of a composition or a patch with no backing can be adhered to opposing mucosal surfaces, e.g., the gum and the cheek or lip, thereby providing added adhesion and a means of simultaneous drug delivery to two mucosal surfaces from the same patch. A composition or a patch of the invention exhibits sustained release of a drug such that a therapeutically effective blood level of the drug can be achieved and/or maintained in a mammal for an extended period of time. Also, a therapeutic level of drug can be maintained in the vicinity of the mucosal surface (e.g., in the oral cavity or the vaginal cavity) if the treatment being effected is local rather than systemic.

In particular embodiments of the invention, a bioadhesive composition or a patch will adhere to human oral mucosa for at least 6 hours, more preferably for at least 8 hours, and most preferably at least 12 hours when tested as described below.

35

Test Method

For purposes of determining the duration of adhesion of a bioadhesive composition of the invention to human oral mucosa, the following method (hereinafter referred to as the "Test Method") is employed as follows.

Step 1. A bioadhesive composition is made into individual patches as follows: An appropriate amount of a substantially solvent-free sample of the bioadhesive composition is placed in a two-roll mill and milled at room temperature until a substantially uniform composition obtains. The composition is then pressed between 2 sheets of silicone-coated release liner in a double heated platen press at a pressure of 70,000 KPa and a temperature of 50°C to afford the composition in the form of a 1 mm thick sheet. One sheet of the release liner is removed, and the exposed bioadhesive surface is contacted with the adhesive surface of a 20 μ m thick polyurethane backing material that has an acrylate pressure-sensitive adhesive coated thereon, to provide a bioadhesive-coated sheet material. Individual patches are then die cut using a 1 cm² circular die.

Step 2. A total of six healthy subjects (3 male, 3 female) between the ages of 25 and 55 years who have been otherwise selected randomly are studied. The subjects fast for at least 1 h prior to the placement of the patch. The release liner (if any) of a patch is removed and the patch is pressed into place with a minimal force (i.e., a force sufficient to allow the patch to adhere but not so great as to cause discomfort) on the oral mucosa of a subject [i.e., at the location prescribed by the instructions (e.g., a package insert) accompanying the particular patch being tested, or absent such instructions, on the upper gingival mucosa above a canine tooth] and held there for several seconds, care being taken to assure that the exposed bioadhesive surface of the patch is not contacted with moist skin, water, mucous, or a mucosal surface prior to placement. The data in the examples below involve placement on the upper gingival

5 mucosa above a canine tooth. If the patch does not adhere
to a particular subject, an attempt is made to adhere a
second patch. If the second patch does not adhere, that
subject is dismissed from the study and replaced with
10 another subject selected as set forth above. Once the
patch is in place, the subjects engage in the normal
activities of daily living, taking care to not forcibly
dislodge the patch, e.g., with their tongue, a toothbrush,
or while chewing food. If the patch is forcibly dislodged
15 during the study, a new patch is placed as described above
and the study with respect to that subject is begun anew.
The elapsed time in hours before the patch loses adhesion
as noted by the subject is measured and recorded. The
average elapsed time in hours observed for the six
20 subjects is then determined. Should it be desired to
measure disintegration over a designated period of time by
the Test Method, the backing (if any) of the patch is
removed prior to placement of the patch, the area covered
by the patch after adhesion for the designated period is
noted, and the average area that remains covered in the
six subjects is determined.

25 In one embodiment of the invention, a
bioadhesive composition exhibits a duration of adhesion of
at least about 6 hours when tested according to this Test
Method.

30 For purposes of determining the duration of
adhesion of a patch of the invention to human oral mucosa,
whether the patch has been prepared according to Step 1 of
the Test Method or otherwise, Step 2 of the Test Method is
employed.

35 In one embodiment of the invention, a patch of
the invention exhibits a duration of adhesion of at least
about 6 hours when tested according to Step 2 of the Test
Method.

The procedures described below set forth non-limiting methods of preparing partially neutralized resins suitable for use in a bioadhesive composition of the invention. Other methods can also be employed if a partially neutralized resin is desired.

Preparative Method 1

CARBOPOLTM 934 P resin (200 g) and calcium hydroxide (15 g, particle size about 25 μ m) were placed in a 5 quart Hobart mixer (Model N-50, Hobart Corp., Troy, OH) and mixed for 5 minutes at a setting of 1. Stirring was continued and isopropyl alcohol (about 200 mL) was added dropwise to the mixture over a period of about 5 minutes, resulting in a material of a dough-like consistency. This material was dried overnight in a tray oven at 90°C, and milled in a small mill (Fitzpatrick Model J, Fitzpatrick Co., Elmhurst, IL) to afford a resin in the form of a powder with a particle size of about 30-50 μ m.

Preparative Method 2

CARBOPOLTM 934 P resin (10 g) was added slowly to ethyl alcohol (500 mL). The resulting mixture was stirred vigorously with a magnetic stirrer until the resin was homogeneously suspended. An aqueous solution of calcium hydroxide (780 mL of a solution containing 1 g/L, 780 mg) was added and the mixture was placed in a screw top jar. The jar was placed in an Eberbach laboratory shaker and shaken overnight at room temperature. The resulting mixture was spray dried using a Buchi Model 190 Mini-Spray Drier (Buchi Laboratories, Flawil, Switzerland). A free-flowing powder (5 g) resulted.

Preparative Method 3

CARBOPOLTM 934 P resin (10 g) was added slowly to ethyl alcohol (500 mL). The resulting mixture was stirred vigorously until the resin was homogeneously suspended. An aqueous solution of aluminum hydroxide (0.91 g in 600 mL water) was added, and the mixture was stirred and dried as set forth in Preparative Method 2.

Preparative Method 4

CARBOPOLTM 934 P resin (300 g) and calcium hydroxide (38 g, particle size about 25 μ m) were placed in a 5 quart Hobart mixer and mixed for about 5 minutes at a setting of 1. Stirring was continued and isopropyl alcohol (about 300 mL) was added uniformly over a period of about 5 minutes. The resulting material was dried and milled according to Preparative Method 1 to afford a resin in the form of a powder with a particle size of about 30-50 μ m.

The following examples are provided to illustrate the invention. They are not intended to limit the invention. All parts and percentages are by weight unless otherwise indicated. When placebo patches were used to determine adhesion to human buccal mucosa, the duration of adhesion represents the length of time that a patch adhered in one person, unless it is indicated that the Test Method was used.

EXAMPLE 1

A solution containing a polyisobutylene with a viscosity average molecular weight of about 53,000 (1.6 g, as 3.2 g of a stock solution containing 50% by weight VISTANEXTM LM-MH polyisobutylene, commercially available from Exxon Chemical Co., Houston, TX, in a 1:1 mixture by

volume of hexane and toluene) and a polyisobutylene with a viscosity average molecular weight of about 1,200,000 (0.080 g, as 0.4 g of a stock solution containing 20% by weight of VISTANEXTM L-100 polyisobutylene, also commercially available from Exxon Chemical Co., in a 1:1 mixture by volume of hexane and toluene) was prepared. Resin obtained from Preparative Method 2 (3.0 g) was added with stirring. A 1:1 solution of hexane and toluene (5 mL) was added and stirring continued for about 5 minutes. The mixture was then coated using a knife coater onto silicone-coated release liner at a wet thickness of 3.4 mm. The solvent was allowed to evaporate. A backing material, TEGADERMTM 1625 brand surgical dressing, was applied by hand to the exposed surface of the coating to provide a composition with a backing material applied thereto. Individual patches were hand-cut from this sheet material with a 1 cm² circular die.

EXAMPLES 2-4

To prepare the bioadhesive composition of EXAMPLE 2, a solution containing VISTANEXTM L-100 polyisobutylene (0.35 g as 1.75 g of a stock solution containing 20% VISTANEXTM L-100 polyisobutylene by weight in a 1:1 mixture by volume of hexane and toluene) and VISTANEXTM LM-MH polyisobutylene (1.60 g as 3.2 g of a stock solution containing 50% VISTANEXTM LM-MH polyisobutylene by weight in a 1:1 mixture by volume of hexane and toluene) was prepared. Digoxin (0.05 g) was added with stirring. Resin obtained from Preparative Method 2 (3.0 g) was added with stirring. A 1:1 mixture by volume of toluene and hexane (5 mL) was added, and stirring was continued for about 5 minutes. The resulting mixture was made into patches according to the method of EXAMPLE 1.

Similarly, using the same relative amounts of components, resin obtained from Preparative Method 3 was

combined with digoxin and incorporated into a patch of
EXAMPLE 3, and resin obtained from Preparative Method 4
was combined with digoxin and incorporated into a patch of
EXAMPLE 4. The patches of EXAMPLES 2-4 were tested
5 according to the In Vivo Test of Sustained Release
described below.

In Vivo Test of Sustained Release

10 A patch of the invention was pressed in place on
the buccal mucosa of a female beagle dog. Blood samples
were drawn periodically after the placement of the patch
and the blood level of the drug was determined by a
standard assay for digoxin.

15 Results are shown in TABLE I, wherein the
absence of an entry indicates a blood level of drug below
the detection limit of the assay.

TABLE I
Blood Levels of Digoxin (ng/mL)

20	Time (hours)	<u>Example</u>		
		<u>2</u>	<u>3</u>	<u>4</u>
	0.5	0.08	0.10	--
	1	0.37	--	0.58
25	2	0.54	2.19	0.08
	3	0.57	1.49	0.02
	4	0.83	2.33	0.04
	5	0.94	3.23	0.11
	6	0.82	5.64	0.02
30	8	1.18	5.34	0.04
	12	2.56	4.91	0.29
	24	3.64	3.50	0.85

35

The patches adhered for the 24 hour period during which blood samples were drawn. TABLE I shows that the bioavailability of the digoxin is substantial for a period of at least 24 h and that digoxin is delivered in a sustained fashion from these bioadhesive compositions of the invention.

EXAMPLES 5-7

Solutions containing VISTANEXTM L-100 polyisobutylene (0.25 g, as 1.25 g of a solution containing 20% VISTANEXTM L-100 polyisobutylene by weight in a 1:1 mixture by volume of hexane and toluene) and VISTANEXTM LM-MH polyisobutylene (1.0 g, as 2.00 g of a solution containing 50% VISTANEXTM LM-MH polyisobutylene by weight in a 1:1 mixture by volume of hexane and toluene) were prepared. The solutions were combined, and theophylline (0.75 g) was added with stirring. Resins obtained from Preparative Methods 2, 3, and 4 (3.0 g) were independently added with stirring. The resulting mixtures were made into patches of EXAMPLES 5, 6, and 7, respectively, according to the method set forth in EXAMPLE 1.

EXAMPLES 8-14

Using the general method of EXAMPLES 2-4, individual patches comprising the compositions listed in TABLE II below, wherein the elastomer is a 1:4 mixture of VISTANEXTM L-100 polyisobutylene and VISTANEXTM LM-MH polyisobutylene, were prepared. TABLE II lists the resin used and the amount thereof, the type and amount of drug used, and the amount of elastomer used. All amounts are based upon the total weight of the bioadhesive composition.

TABLE II

<u>Example</u>	<u>Resin (%)</u>	<u>% Elastomer</u>	<u>Drug (%)</u>
5	8	CARBOPOL TM 934P (45%)	40% Morphine (15%)
	9	CARBOPOL TM 951 (45%)	40% Morphine (15%)
	10	CARBOPOL TM 910 (50%)	35% Morphine (15%)
10	11	CARBOPOL TM 910 (45%)	40% Morphine (15%)
	12	CARBOPOL TM 910 (50%)	35% Morphine Sulfate (15%)
	13	CARBOPOL TM 910 (45%)	40% Morphine Sulfate (15%)
15	14	CARBOPOL TM 910 (50%)	35% Morphine HCl (15%)

20 Patches of EXAMPLES 10, 12, and 14 were tested according to the In Vivo Test of Sustained Release (set forth in EXAMPLES 2-4 above) with a standard assay for morphine being employed. The results are shown in TABLE III.

25

30

35

TABLE III
Blood Levels of Morphine (ng/mL)

<u>Time (hours)</u>		<u>Example</u> <u>10</u>	<u>Example</u> <u>12</u>	<u>Example</u> <u>14</u>
5	1	11	8	17
	2	18	15	38
	3	18	19	76
	4	16	26	26
	6	25	16	59
	8	13	12	33
10	10	25	10	19
	12	16	10	12
	24	49	16	--

The patches adhered throughout the 24 hour period during which blood samples were drawn. TABLE III shows that the bioavailability of morphine, morphine HCl, and morphine sulfate is substantial for a period of at least 24 h, and that these drugs are released from these compositions of the invention in a sustained fashion.

EXAMPLES 15-25

Using the general method of EXAMPLE 1, 5.0 g samples of the bioadhesive compositions set forth in TABLE IV below were prepared. All amounts are based upon the total weight of the bioadhesive composition. Individual patches were prepared according to the general method of EXAMPLE 1 and remained adhered to human buccal mucosa for a study period indicated in TABLE IV. The study period was terminated by removing the patch by hand. No entry indicates that the patch was adhered but was removed after a short time. Patches of EXAMPLES 20 and 24 were tested for in vivo adhesion in humans according to Step (2) of the Test Method set forth above. The results are shown in TABLE V below.

TABLE IV

	COMPONENT	EXAMPLE (wt %)					
		<u>15</u>	<u>16</u>	<u>17</u>	<u>18</u>	<u>19</u>	<u>20</u>
5	CARBOPOL™ 910	50	60	40	--	--	--
	CARBOPOL™ 934P	--	--	--	--	--	60
	CARBOPOL™ 940	--	--	--	60	--	--
	CARBOPOL™ 941	--	--	--	--	60	--
	CARBOPOL™ 951	--	--	--	--	--	--
10	CARBOPOL™ 1342	--	--	--	--	--	--
	VISTANEX™ LMMH	40	32	48	32	32	32
	VISTANEX™ L100	10	8	12	8	8	8
	Study Period	24h	24h	--	2h	2h	24h
15	COMPONENT	EXAMPLE (wt %)					
		<u>21</u>	<u>22</u>	<u>23</u>	<u>24</u>	<u>25</u>	
20	CARBOPOL™ 910	--	--	--	--	--	
	CARBOPOL™ 934P	50	40	--	--	--	
	CARBOPOL™ 941	--	--	--	--	--	
	CARBOPOL™ 951	--	--	40	60	--	
	CARBOPOL™ 1342	--	--	--	--	60	
	VISTANEX™ LMMH	40	48	48	32	32	
	VISTANEX™ L100	10	12	12	8	8	
25	Study Period	24h	--	20h	24h	4h	

TABLE V

Duration of Adhesion (hours)		
30	Subject	Patch of
		Example 20
35	A	26
	B	30
	C	23
	D	20
	E	13
	F	9
Average ($\pm \sigma$)		20.2 (± 7.3)
		Patch of
		Example 24
		15
		24
		23
		24
		22
		14
		20.3 (± 4.2)

The data in TABLE V show that these patches of the invention adhere to human oral mucosa for an extended period of time.

EXAMPLES 26-29

CARBOPOLTM 910 resin (100g) was placed in a Hobart mixer (Model N-50, Hobart Corp., Troy, OH) and mixed at a setting of 1 while isopropyl alcohol (100 ml) was added dropwise over a period of about 5 minutes. The resulting material was dried overnight in a tray oven at 32°C and milled in a small mill (Fitzpatrick Model J, Fitzpatrick Co., Elmhurst, IL) to afford CARBOPOLTM 910 resin with an average particle size of about 30 μ m to 50 μ m.

Using the general method of EXAMPLE 1, and the CARBOPOLTM 910 resin as processed above, 5.0 g samples of the bioadhesive compositions set forth in TABLE VI were prepared. All amounts are based upon the total weight of the bioadhesive composition. Individual patches were prepared according to the general method of EXAMPLE 1 and remained adhered to human buccal mucosa for a study period of about 20 hours. The study period was terminated by removing the patch by hand.

TABLE VI

Example				
No.	%CARBOPOL TM 910	%VISTANEX TM LM-MH	%VISTANEX TM L-100	
26	50	40	10	
27	60	32	8	
28	70	24	6	
29	75	20	5	

EXAMPLES 30-32

Using the general method of EXAMPLE 1, 5.0 g samples of the compositions set forth in TABLE VII below were prepared. All amounts are based upon the total weight of the bioadhesive composition. The polyacrylic acid samples were purchased from Polysciences, Inc., Warrington, PA. Individual patches were prepared according to the general method of EXAMPLE 1 and remained adhered to human buccal mucosa for a study period of about 4 hours. The study period was terminated by removing the patch by hand.

TABLE VII

Example No.	% Polyacrylic Acid (MW)	%VISTANEX TM LMMH	%VISTANEX TM L100
30	50 (450,000)	40	10
31	50 (1,000,000)	40	10
32	50 (4,000,000)	40	10

EXAMPLE 33

A solution (5.0 g) containing 70% by weight toluene, 10% by weight mineral oil, and 20% by weight of KratonTMD 1107 rubber was prepared. Polycarbophil (Biomimetics, Inc., Lexington, MA) was added over a period of about 5 minutes with stirring. Patches were made from the resulting mixture as described in EXAMPLE 1. The patches remained strongly adhered to human buccal mucosa for a study period of several minutes. The study period was terminated by removing the patch by hand.

EXAMPLES 34 and 35

5 A copolymer of 96% by weight isooctylacrylate
and 4% by weight acrylamide (prepared according to the
method of Example 2 of U.S. Pat. No. 4,751,087 (Wick), the
entire disclosure of which is incorporated herein by
reference) was dissolved in a 90:10 (V/V) solution of
ethyl acetate in methanol in an amount sufficient to
prepare a 30% by weight solution of the copolymer. To an
10 aliquot of the solution was added with stirring
polycarbophil (Biomimetics, Inc., Lexington, MA) in an
amount sufficient to prepare the compositions set forth in
TABLE VIII below.

TABLE VIII

<u>Example</u>	<u>% Elastomer</u>	<u>% polycarbophil</u>
34	25	75
35	20	80

20 The compositions of TABLE VIII were made into
patches according to the general method of EXAMPLE 1. The
patches remained adhered strongly to human buccal mucosa
for a study period of about 2 hours. The study period was
25 terminated by removing the patch by hand.

EXAMPLES 36-43

30 Compositions were prepared by milling the
components listed in TABLE IX at room temperature in a
two-roll mill (Reliable Mill Model 3216, Rubber and
Plaster Machine Company, North Bergen, NJ) according to
the general method set forth below.

35 The lower molecular weight component of the
elastomer was added to the mill and milled until it was
distributed on the rollers. The higher molecular weight
component of the elastomer was then added as small pieces

and milling was continued until a homogeneous mixture obtained. The plasticizer (if any) was then added and the mixture was milled until homogeneous.

5 The particulate polymeric resin was mixed with the drug (if any) to form a uniform mixture. The resin was then added slowly to the elastomeric component in the mill and this mixture was milled until a uniform composition obtained. It was necessary to periodically remove the material from the rollers, form it into a ball and re-mill to ensure a uniform composition. The composition was removed from the mill by scraping the rollers.

15 About 15 to 25g of the composition was pressed at about 70,000 KPa between two 17 cm x 17 cm pieces of silicone-coated release liner in a platen press heated to about 50°C to afford a laminate comprising a sheet of composition about 2 mm thick. Individual patches were cut from the resulting laminate with a die.

20 Compositions were prepared as described above using the materials set forth in TABLE IX below . Individual patches were found to adhere to human oral mucosa.

TABLE IX

Component	Example Number							
	36	37	38	39	40	41	42	43
polycarbophil*	30g	30g	30g			30g	30g	30g
CARBOPOL™ 934-P				90g	35g			
LIR-50**	12g							
LIR-410**		12g						
LIR-506**			12g					
VISTANEX™ L-100	8g	8g	8g		9.8g	4g	4g	4g
VISTANEX™ L-80				30g				
VISTANEX™ LM-MH					4.5g	16g	16g	16g
mineral oil						3g		
corn oil***							3g	
silicone oil****								3g

- * from Biomimetics, Inc., Lexington, MA
- ** from Arakawa Chemical, Chicago, IL
- *** MAZOLATM Corn Oil
- 5 **** Dow Corning 200 fluid, 200 cps

EXAMPLES 44-47

10 Compositions were prepared according to the general method set forth in EXAMPLES 36-43 above using the components shown in TABLE X below. TEGADERMTM 1625 surgical dressing was adhered as a backing to one side of the compositions.

15

		<u>TABLE X</u>			
		<u>Example</u>			
<u>Component</u>		<u>44</u>	<u>45</u>	<u>46</u>	<u>47</u>
Vistanex TM LM-MH		16g	16g	8g	9.6g
Vistanex TM L-100		4g	4g	2g	2.4g
20 Polycarbophil*		30g	30g	15g	16g
Theophylline		10g			
Digoxin				0.2g	
Estradiol			0.53g		
Nitroglycerin					2.0g

- 25 * Biomimetics, Inc., Lexington, MA

30 Individual patches of the composition of EXAMPLE 44 were prepared and placed on the gum of a female beagle dog and blood levels of the drug were measured using a standard assay. The results are shown below.

Theophylline level		
	<u>Time (hr)</u>	<u>(μg/mL)</u>
5	1	0.5
	3	1.0
	5	1.4
	7	1.4
	10	1.2
10	14	1.2
	21	1.4
	24	1.2

The patch was removed after 24 hours

15 Individual patches of the composition of EXAMPLE 45 were prepared and two patches were placed on the gum of a female beagle dog and blood levels of both estradiol and estrone were measured using standard assays. The results are shown below.

	Estradiol		Estrone
	<u>Time (hr)</u>	<u>level (pg/mL)</u>	<u>level (pg/mL)</u>
20	Predose	<5	12
	0.25	13	46
	0.5	17	87
	1.0	39	170
	1.5	58	230
	2.0	43	220
	3.0	330	1090
25	4	230	780
	6	190	410
	8	870	2040
	24	110	420
	25	39	130
30	30	13	40

The patch was removed at 24 hours

Individual patches of the composition of EXAMPLE 46 were prepared and placed on the gum or the cheek of a female beagle dog as indicated below and blood levels of the drug were measured using a standard assay. The results are shown below, where nd designates that no determination of blood level of drug was made.

	Time (hr)	Digoxin level (ng/mL)	
		Gum	Cheek
10	0.5	<0.1	<0.1
	1	<0.1	0.5
	2	0.13	0.52
	3	0.13	1.3
	4	0.45	1.1
15	5	0.38	1.77
	6	0.38	nd
	7	0.47	nd

The patch was removed at 8 hours

Individual patches of the composition of EXAMPLE 47 were prepared and placed on the inner surface of the upper lip of a female beagle dog and blood levels of the drug were measured using a standard assay. The results are shown below.

	Nitroglycerin level	
	Time (hr)	(ng/mL)
	Predose	0.0
	1	2.5
30	2	4.3
	3	4.5
	4	13.0
	5	12.8
	6	0.60

The patch was removed at 5 hours

In all cases, therapeutic levels of the respective drug were observed for a sustained period of time.

EXAMPLES 48-53

5

Compositions were prepared by milling at room temperature in a two-roll mill (Model Number 53060 Farrell-Birmingham Ansonia CT) with rollers of 15 cm diameter and 30 cm length according to the general method set forth below. The elastomeric component or, in the case of a two-component elastomeric component, the higher molecular weight component, was added to the mill in portions and milled until uniform (about 15 minutes) and rolled into a sheet. The sheet was placed in the mill, and the resin or, in the case of a two-component elastomeric component, the resin and the lower molecular weight component together, were added slowly and milled until a uniform composition obtained. The drug was then added and milling was continued until the drug was uniformly distributed in the composition (about 15 minutes). The composition was then rolled out of the mill in the form of a sheet by adjusting the space between the rollers such that a sheet of the desired thickness (e.g., 1-2 mm) was produced. Individual patches were cut from the resulting sheet with a 1 cm² circular die.

10

15

20

25

Compositions were prepared as described above using the components set forth in TABLE XI below.

Using conventional methods, the compositions of EXAMPLES 48, 49, and 50 were found to have uniform drug content throughout the compositions. A patch of the composition of EXAMPLE 51 remained adhered to the buccal mucosa of a female beagle dog for a study period of 24 hours. Patches of the compositions of EXAMPLES 52 and 53 remained adhered to human buccal mucosa for a study period of about 8 hours and about 15 hours, respectively. The study periods were terminated by removing the patches by hand.

30

35

SECRET

Example	Component (wt. %)					Morphine Sulfate
	<u>Vistanex™ L-100</u>	<u>Vistanex™ L-80</u>	<u>Vistanex™ LMMH</u>	<u>Carbopol™ 934P</u>	<u>Theophylline</u>	
48	17	---	8.5	59.5		15
49		21.25		63.75		15
50		22.5		67.5	10	
51	20			60		20
52		25		75		
53	20		10	70		

EXAMPLE 54

5 A composition was prepared according to the
general method of EXAMPLES 36-43 using 60% by weight
polycarbophil, 32% by weight VISTANEXTM LMMH
polyisobutylene, and 8% by weight VISTANEXTM L-100
polyisobutylene. A circular patch of 1.2 cm diameter was
prepared and placed in the vaginal cavity of a sheep.
10 After a period of about 20 hours, the patch was still
adhering well and was slightly swollen. After a period of
about 44 hours, the patch was still adhering well, but
some disintegration was observed. After a period of about
70 hours, the patch was still adhering but it was soft and
15 swollen. The patch was removed by gentle scraping with a
spatula.

EXAMPLE 55

20 A multi-layer gradient composition was prepared
as follows:

An approximately square sheet with an area of
about 25 cm² of the solvent-cast composition of EXAMPLE 15
was prepared.

25 An approximately square sheet with an area of
about 25 cm² of a composition was prepared by the general
milling method of EXAMPLES 48-53 using 75% by weight of
CARBOPOLTM 934P resin and 25% by weight VISTANEXTM L-80
polyisobutylene.

30 As a backing layer, an approximately square
sheet with an area of about 25 cm² of VISTANEXTM L-100
polyisobutylene was prepared according to the general
method of EXAMPLE 1 (absent the resin and the backing), by
solvent casting the solution of elastomer at a wet
35 thickness of about 0.5 mm.

The three sheets were stacked with the milled patch in the middle. The stacked compositions were pressed between two sheets of release liner in a heated platen press at 38°C and 35,000 KPa. A 1 cm² circular patch was cut from the resulting composition. The patch remained adhered to human gingival mucosa for a study period of about 14 hours. The study period was terminated by removing the patch by hand. The layers of the patch showed no sign of de-laminating, and the polyisobutylene backing layer prevented adhesion of the patch to the mucosal surface opposite the gum.

EXAMPLES 56-58

Patches were prepared according to the general method of EXAMPLES 48-53 above, using the components set forth in TABLE XIII below.

TABLE XII

Example	NATSYN TM 2210	Component (wt. %)		Theophylline
		NATSYN TM 2205	CARBOPOL TM 934P	
56	20	--	50	30
57	20	--	60	20
58	--	20	60	20

The above-described patches were independently adhered to a glass slide using double-stick tape and tested for in vitro release of theophylline by immersing the patches in 700 mL of pH 7 buffer solution in a USP Type II dissolution apparatus. Periodically, a 5 mL aliquot of the buffer was removed and analyzed by ultraviolet spectrophotometry (270 nm) for theophylline. Results are as shown in TABLE XIII below.

TABLE XIII

		% theophylline released		
		Example		
	Time (hours)	56	57	58
5	0.25	9.66	8.64	11.08
	0.50	14.66	13.18	17.16
	1.0	22.60	20.76	26.76
	1.5	29.45	27.35	35.68
	2	35.34	33.03	44.32
10	3	46.03	43.56	60.27
	4	55.48	53.33	73.24
	5	63.84	61.97	82.70
	6	71.23	69.62	90.00
	7	77.40	76.29	94.46
15	8	83.56	81.82	97.30
	16	100	100	100

The data in TABLE XIII show that these compositions of the invention release theophylline in a sustained fashion in vitro.

EXAMPLE 59

A patch was prepared using 20 weight percent NATSYN™ 2210 polyisoprene (Goodyear, molecular weight about 760,000), 50 weight percent CARBOPOL™ 934P resin, and 30 weight percent morphine sulfate, with the sheet of composition being pressed at about 70°C and about 70,000 KPa for about 20 seconds prior to cutting into patches. Morphine sulfate release in vitro was determined as described above in connection with EXAMPLES 56-58, with the buffer aliquot being analyzed for morphine by the USP method. Results are shown in TABLE XIV below.

TABLE XIV

	<u>Time (minutes)</u>	<u>% morphine released</u>
	20	1.34
5	30	2.79
	60	6.43
	90	8.25
	120	11.75
	180	15.62
10	240	19.60
	360	27.21
	480	33.67
	600	40.33
	720	44.58

The data in TABLE XIV show that the composition of EXAMPLE 59 releases morphine sulfate in a sustained fashion in vitro.

EXAMPLE 60

A patch was prepared according to the general method of EXAMPLES 48-53 using 30 weight percent NATSYNTM2205 polyisoprene (molecular weight about 955,000) and 70 weight percent CARBOPOLTM934P resin. The patch was adhered to the gingival mucosa of a subject and remained adhered for a study period of about 8 hours, after which time the study period was terminated and the patch was removed from the mucosa.

EXAMPLE 61

A patch was prepared according to the general method of EXAMPLES 48-53 above using 30 weight percent TAKTENETM1202 polybutadiene (Polysar, molecular weight about 375,000) and 70 weight percent CARBOPOLTM934P resin. The patch was placed on the gingival mucosa of a subject

and remained adhered for a study period of about 7 hours after which time the study period was terminated and the patch was removed from the mucosa.

EXAMPLES 62-63

5

Two different embodiments of patches were prepared according to the general method of EXAMPLES 48-53 above, using, respectively, 5 weight percent
10 TAKTENETM1202 polybutadiene (molecular weight about 335,000), 25 weight percent NATSYNTM2210 polyisoprene (molecular weight about 760,000), and 70 weight percent CARBOPOLTM934P resin; and 25 weight percent TAKTENETM1220 polybutadiene, 5 weight percent NATSYNTM2210 polyisoprene,
15 and 70 weight percent CARBOPOLTM934P resin, with the respective sheets being pressed as described in Example 59 above prior to cutting into patches.

The patches were found to adhere to human oral mucosa.

20

EXAMPLE 64

According to the general method of EXAMPLE 1 above, a composition of the invention was prepared using
25 45 weight percent CARBOPOLTM934P resin, 18 weight percent VISTANEXTM L-100 polyisobutylene, 27 weight percent VISTANEXTM LMMH polyisobutylene, and 10 weight percent melatonin. Patches made from this composition were placed on the oral mucosa of dogs and found to provide
30 therapeutically effective blood levels of melatonin.

35

Claims:

1. A bioadhesive composition that comprises:
 - 1) a particulate polymeric resin with an
5 average particle size of less than or equal to
about 100 μ m and comprising at least about 55% by
weight of carboxylic acid moieties based on the
total weight of the polymeric resin;
 - 2) from about 20 parts to about 250 parts
10 by weight of a hydrophobic elastomeric component,
based on 100 parts by weight of the resin; and
 - 3) an amount of a drug effective to
provide a desired therapeutic result,
wherein the resin and the drug are dispersed substantially
15 throughout the elastomeric component, and which
composition contains less than about 10% water by weight
based on the weight of the polymeric resin, exhibits
substantially no instantaneous adhesion to dry skin, and
adheres to a mucosal surface.
2. A composition according to Claim 1, wherein
20 the hydrophobic elastomeric component comprises a block
styrene-butadiene-styrene copolymer, a block styrene-
isoprene-styrene copolymer, a polyisobutylene, a
polybutadiene, an isoprene rubber, a carboxy-functional
polyisoprene, a hydroxy-functional polyisoprene, an
25 acrylate elastomer, or a mixture of two or more of the
foregoing.
3. A composition according to Claim 1, wherein
the elastomeric component comprises a plasticizer.
- 30 4. A composition according to Claim 1, wherein
the polymeric resin consists essentially of acrylic acid
monomer units.
5. A composition according to Claim 4, wherein
the resin is covalently crosslinked with about 0.75% to
35 about 2% by weight based on the total weight of the resin
of a polyalkenyl polyether.

6. A composition according to Claim 1, wherein up to about 30% of the carboxylic acid moieties of the resin are neutralized by a base.

5 7. A composition according to Claim 6, wherein the base is selected from the group consisting of $\text{Al}(\text{OH})_3$ and $\text{Ca}(\text{OH})_2$.

8. A composition according to Claim 6, wherein the base is a polyamine.

10 9. A composition according to Claim 1, wherein the elastomeric component is a hydrocarbon.

15 10. A composition according to Claim 9, wherein the elastomeric component comprises a polyisoprene with a molecular weight of about 500,000 to about 1,200,000 a polybutadiene with a molecular weight of about 100,000 to about 500,000, or a mixture thereof.

20 11. A composition according to Claim 9, wherein the elastomeric component is a mixture comprising about 5% to about 50% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 50% to about 95% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

25 12. A composition according to Claim 9, wherein the elastomeric component is a mixture comprising about 15% to about 25% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 75% to about 85% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

30 13. A composition according to Claim 9, wherein the elastomeric component is a mixture comprising about 20% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 80% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

35

14. A composition according to Claim 9, wherein the elastomeric component is a mixture comprising about 20% by weight of a polyisobutylene with a viscosity average molecular weight about 1.25 million and about 80% by weight of a polyisobutylene with a viscosity average molecular weight about 53,000.

15. A composition according to Claim 1, prepared by a process comprising the steps of:

- 1) adding to a mill the constituent or constituents of the elastomeric component;
- 2) milling the constituent or constituents of the elastomeric component to afford a substantially homogeneous elastomeric component;
- 3) milling the particulate polymeric resin, the drug, and the substantially homogeneous elastomeric component from step (2) to form a homogeneous composition.

16. A composition according to Claim 15, wherein the constituents of the elastomeric component comprise: about 5% to about 50% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million; and about 50% to about 95% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

17. A composition according to Claim 15, wherein the constituents of the elastomeric component comprise: about 15% to about 25% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 75% to about 85% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

18. A composition according to Claim 15, wherein the constituents of the elastomeric component comprise: about 20% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000

and about 2.5 million, and about 80% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

19. A composition according to Claim 15,
5 wherein the constituents of the elastomeric component comprise: about 20% by weight of a polyisobutylene with a viscosity average molecular weight about 1.25 million and about 80% by weight of a polyisobutylene with a viscosity average molecular weight about 53,000.

20. A composition according to Claim 15,
10 wherein the constituents of the elastomeric component comprise: about 60% to 100% of a polyisobutylene with a viscosity average molecular weight of about 750,000 to about 1,500,000; and 0% to about 40% of a polyisobutylene
15 with a viscosity average molecular weight of about 40,000 to about 100,000.

21. A composition according to Claim 15,
wherein the constituents of the elastomeric component are selected from the group consisting of a polyisoprene with a molecular weight of about 500,000 to about 1,200,000, a
20 polybutadiene with a molecular weight of about 100,000 to about 500,000, a mixture of two or more of said polyisoprenes, a mixture of two or more of said polybutadienes, and a mixture of one or more of said
25 polyisoprenes and one or more of said polybutadienes.

22. A composition according to Claim 1, wherein the resin has an average particle size between about 1 μm and about 80 μm .

23. A composition according to Claim 1, wherein the resin has an average particle size of between about
30 2 μm and about 10 μm .

24. A composition according to Claim 1,
comprising about 20 to about 150 parts by weight of the elastomeric component based on 100 parts by weight of the
35 resin.

25. A composition according to Claim 1, comprising about 25 to about 75 parts by weight of the elastomeric component based on 100 parts by weight of the resin.

5 26. A composition according to Claim 1, which contains less than about 4% water by weight based on the total weight of the resin.

 27. A composition according to Claim 1, which contains less than about 2% water by weight based on the
10 total weight of the resin.

 28. A composition according to Claim 1, wherein the drug is one that exhibits systemic action.

 29. A composition according to Claim 1, wherein the drug is a narcotic analgesic.

15 30. A composition according to Claim 1, wherein the drug is morphine or a pharmaceutically acceptable salt thereof.

 31. A composition according to Claim 1, wherein the drug is selected from the group consisting of digoxin, heparin, hydromorphone, buprenorphine, theophylline,
20 melatonin, and pharmaceutically acceptable salts thereof.

 32. A composition according to Claim 1, wherein the resin is distributed substantially uniformly throughout the elastomeric component.

25 33. A composition according to Claim 1, wherein the resin is distributed throughout the elastomeric component in a suitable gradient.

 34. A composition according to Claim 1, wherein the drug is distributed substantially uniformly throughout the elastomeric component.
30

 35. A composition according to Claim 1, wherein the drug is distributed throughout the elastomeric component in a suitable gradient.

35 36. A composition according to Claim 1, wherein the drug is absorbed into the resin, adsorbed on the resin, or ionically bound to the resin.

37. A process for preparing a composition according to Claim 1 in a mill which process comprises the steps of:

- 1) milling the elastomeric component to afford a substantially homogeneous elastomeric component;
- 2) milling the particulate polymeric resin, the drug, and the substantially homogeneous elastomeric component from step (1) to form a substantially homogeneous composition.

38. A process according to Claim 37 wherein the drug is absorbed into the resin, adsorbed on the resin, or ionically bound to the resin prior to step (2).

39. A process for preparing a composition according to Claim 1, comprising the steps of:

- (1) dissolving the elastomeric component in a volatile organic solvent;
- (2) dispersing the resin and the drug substantially uniformly in the solution formed in step (1); and
- (3) removing the solvent from the dispersion of step (2).

40. A process according to Claim 39, wherein the drug is absorbed into the resin, adsorbed on the resin, or ionically bound to the resin prior to step (2).

41. A sheet material comprising a composition according to Claim 1 with a flexible film backing applied thereto.

42. A bioadhesive composition that comprises:

- 1) a particulate polymeric resin with an average particle size of less than or equal to about 100 μm and comprising at least about 55% by weight of carboxylic acid moieties based on the total weight of the polymeric resin;
- 2) from about 20 parts to about 250 parts by weight of a hydrophobic elastomeric component, based on 100 parts by weight of the resin; and

3) an amount of a drug effective to provide a desired therapeutic result, wherein the resin and the drug are dispersed substantially throughout the elastomeric component, and which composition contains less than about 10% water by weight based on the weight of the polymeric resin, exhibits substantially no instantaneous adhesion to dry skin, adheres to a mucosal surface, and exhibits a duration of adhesion to human oral mucosa of at least about 6 hours when tested according to the Test Method.

43. A composition according to Claim 42, which exhibits a duration of adhesion of at least about 8 hours when tested according to the Test Method.

44. A composition according to Claim 42, which exhibits a duration of adhesion of at least about 12 hours when tested according to the Test Method.

45. A composition according to Claim 42, wherein the hydrophobic elastomeric component comprises a block styrene-butadiene-styrene copolymer, a block styrene-isoprene-styrene copolymer, a polyisobutylene, a polybutadiene, an isoprene rubber, a carboxy-functional polyisoprene, a hydroxy-functional polyisoprene, an acrylate elastomer, or a mixture of two or more of the foregoing.

46. A composition according to Claim 42, wherein the elastomeric component comprises a plasticizer.

47. A composition according to Claim 42, wherein the polymeric resin consists essentially of acrylic acid monomer units.

48. A composition according to Claim 47, wherein the resin is covalently crosslinked with about 0.75% to about 2% by weight based on the total weight of the resin of a polyalkenyl polyether.

49. A composition according to Claim 42, wherein up to about 30% of the carboxylic acid moieties of the resin are neutralized by a base.

50. A composition according to Claim 49, wherein the base is selected from the group consisting of $\text{Al}(\text{OH})_3$ and $\text{Ca}(\text{OH})_2$.

51. A composition according to Claim 49, wherein the base is a polyamine.

52. A composition according to Claim 42, wherein the elastomeric component is a hydrocarbon.

5 53. A composition according to Claim 52, wherein the elastomeric component comprises a polyisoprene with a molecular weight of about 500,000 to about 1,200,000, a polybutadiene with a molecular weight of about 100,000 to about 500,000, or a mixture thereof.

10 54. A composition according to Claim 52, wherein the elastomeric component is a mixture comprising about 5% to about 50% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 50% to about 95% by
15 weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

55. A composition according to Claim 52, wherein the elastomeric component is a mixture comprising about 15% to about 25% by weight of a polyisobutylene with a
20 viscosity average molecular weight between about 500,000 and about 2.5 million, and about 75% to about 85% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

25 56. A composition according to Claim 52, wherein the elastomeric component is a mixture comprising about 20% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 80% by weight of a polyisobutylene with a viscosity average molecular weight between about
30 40,000 and about 100,000.

57. A composition according to Claim 52, wherein the elastomeric component is a mixture comprising about 20% by weight of a polyisobutylene with a viscosity average molecular weight about 1.25 million and about 80%
35 by weight of a polyisobutylene with a viscosity average molecular weight about 53,000.

58. A composition according to Claim 1, prepared by a process comprising the steps of:

1) adding to a mill the constituent or constituents of the elastomeric component;

5 2) milling the constituent or constituents of the elastomeric component to afford a substantially homogeneous elastomeric component;

10 3) milling the particulate polymeric resin, the drug, and the substantially homogeneous elastomeric component from step (2) to form a substantially homogeneous composition.

59. A composition according to Claim 58, wherein the constituents of the elastomeric component comprise: about 5% to about 50% by weight of a
15 polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million; and about 50% to about 95% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

20 60. A composition according to Claim 58, wherein the constituents of the elastomeric component comprise: about 15% to about 25% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 75%
25 to about 85% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

30 61. A composition according to Claim 58, wherein the constituents of the elastomeric component comprise: about 20% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 80% by weight of a
polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

35 62. A composition according to Claim 58, wherein the constituents of the elastomeric component comprise: about 20% by weight of a polyisobutylene with a

viscosity average molecular weight about 1.25 million and about 80% by weight of a polyisobutylene with a viscosity average molecular weight about 53,000.

63. A composition according to Claim 58,
5 wherein the constituents of the elastomeric component
comprise: about 60% to 100% of a polyisobutylene with a
viscosity average molecular weight of about 750,000 to
about 1,500,000; and 0% to about 40% of a polyisobutylene
with a viscosity average molecular weight of about 40,000
10 to about 100,000.

64. A composition according to Claim 58,
wherein the constituents of the elastomeric component are
selected from the group consisting of a polyisoprene with
a molecular weight of about 500,000 to about 1,200,000, a
15 polybutadiene with a molecular weight of about 100,000 to
about 500,000, a mixture of two or more of said
polyisoprenes, a mixture of two or more of said
polybutadienes, and a mixture of one or more of said
polyisoprenes and one or more of said polybutadienes.

65. A composition according to Claim 42,
20 wherein the resin has an average particle size of between
about 1 μm and about 80 μm .

66. A composition according to Claim 42,
wherein the resin has an average particle size of between
25 about 2 μm and about 10 μm .

67. A composition according to Claim 42,
comprising about 20 to about 150 parts by weight of the
elastomeric component based on 100 parts by weight of the
resin.

68. A composition according to Claim 42,
30 comprising about 25 to about 75 parts by weight of the
elastomeric component based on 100 parts by weight of the
resin.

69. A composition according to Claim 42, which
35 contains less than about 4% water by weight based on the
total weight of the resin.

70. A composition according to Claim 42, which contains less than about 2% water by weight based on the total weight of the resin.

71. A composition according to Claim 42,
5 wherein the drug is one that exhibits systemic action.

72. A composition according to Claim 42, wherein the drug is a narcotic analgesic.

73. A composition according to Claim 42, wherein the drug is morphine or a pharmaceutically
10 acceptable salt thereof.

74. A composition according to Claim 42, wherein the drug is selected from the group consisting of digoxin, heparin, hydromorphone, buprenorphine, theophylline, melatonin, and pharmaceutically acceptable
15 salts thereof.

75. A sheet material comprising a composition according to Claim 42 with a flexible film backing applied thereto.

76. A composition according to Claim 42,
20 wherein the resin is distributed substantially uniformly throughout the elastomeric component.

77. A composition according to Claim 42, wherein the resin is distributed throughout the elastomeric component in a suitable gradient.

78. A composition according to Claim 42,
25 wherein the drug is distributed substantially uniformly throughout the elastomeric component.

79. A composition according to Claim 42, wherein the drug is distributed throughout the elastomeric
30 component in a suitable gradient.

80. A composition according to Claim 42, wherein the drug is absorbed into the resin, adsorbed on the resin, or ionically bound to the resin.

81. A process for preparing a composition
35 according to Claim 42 in a mill which process comprises the steps of:

1) milling the elastomeric component to afford a substantially homogeneous elastomeric component;

2) milling the particulate polymeric resin, the drug, and the substantially homogeneous elastomeric component from step (1) to form a substantially homogeneous composition.

5 82. A process according to Claim 81 wherein the drug is absorbed into the resin, adsorbed on the resin, or ionically bound to the resin prior to step (2).

83. A process for preparing a composition according to Claim 42, comprising the steps of:

10 1) dissolving the elastomeric component in a volatile organic solvent;

2) dispersing the resin and the drug substantially uniformly in the solution formed in step (1); and

15 3) removing the solvent from the dispersion of step (2).

84. A process according to Claim 83, wherein the drug is absorbed into the resin, adsorbed on the resin, or ionically bound to the resin prior to step (2).

20 85. A patch comprising

1) a flexible film backing; and

2) a bioadhesive composition on one surface of the flexible film, the bioadhesive composition comprising

25 i) a particulate polymeric resin with an average particle size of less than or equal to about 100 μ m and comprising at least about 55% by weight of carboxylic acid moieties based on the total weight of the polymeric resin;

30 ii) from about 20 parts to about 250 parts by weight of a hydrophobic elastomeric component, based on 100 parts by weight of the resin; and

35 iii) an amount of a drug effective to provide a desired therapeutic effect, wherein the resin and the drug are dispersed substantially

throughout the elastomeric component, and which composition contains less than about 10% water by weight based on the weight of the polymeric resin, exhibits substantially no instantaneous adhesion to dry skin, and adheres to a mucosal surface,

which patch is further characterized in that it exhibits a duration of adhesion to human oral mucosa of at least about 6 hours when tested according to step 2 of the Test Method.

86. A patch according to Claim 85, wherein the hydrophobic elastomeric component comprises a block styrene-butadiene-styrene copolymer, a block styrene-isoprene-styrene copolymer, a polybutadiene, a polyisobutylene, an isoprene rubber, a carboxy-functional polyisoprene, a hydroxy-functional polyisoprene, an acrylate elastomer, or a mixture of two or more of the foregoing.

87. A patch according to Claim 85, wherein the elastomeric component comprises a plasticizer.

88. A patch according to Claim 85, wherein the polymeric resin consists essentially of acrylic acid monomeric units.

89. A patch according to Claim 85, wherein the resin is covalently crosslinked with about 0.75% to about 2% by weight of a polyalkenyl polyether.

90. A patch according to Claim 85, wherein up to about 30% of the carboxylic acid moieties of the resin are neutralized by a base.

91. A patch according to Claim 90, wherein the base is selected from the group consisting of $\text{Al}(\text{OH})_3$ and $\text{Ca}(\text{OH})_2$.

92. A patch according to Claim 90, wherein the base is a polyamine.

93. A patch according to Claim 85, wherein the elastomeric component is a hydrocarbon.

94. A patch according to Claim 93, wherein the elastomeric component comprises a polyisoprene with a molecular weight of about 500,000 to about 1,200,000, a

polybutadiene with a molecular weight of about 100,000 to about 500,000, or a mixture thereof.

5 95. A patch according to Claim 93, wherein the elastomeric component is a mixture comprising about 5% to about 50% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 50% to about 95% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

10 96. A patch according to Claim 93, wherein the elastomeric component is a mixture comprising about 15% to about 25% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 75% to about 85% by weight of a
15 polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

20 97. A patch according to Claim 93, wherein the elastomeric component is a mixture comprising about 20% of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 80% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

25 98. A patch according to Claim 93, wherein the elastomeric component is a mixture comprising about 20% by weight of a polyisobutylene with a viscosity average molecular weight about 1.25 million and about 80% by weight of a polyisobutylene with a viscosity average molecular weight about 53,000.

30 99. A patch according to Claim 85, prepared by a process comprising the steps of:

- 1) adding to a mill the constituent or constituents of the elastomeric component;
- 2) milling the constituent or constituents
35 of the elastomeric component to afford a substantially homogeneous elastomeric component;

3) milling the particulate polymeric resin, the drug, and the substantially homogeneous elastomeric component from step (2) to form a substantially homogeneous composition; and

5 4) applying the flexible film backing to the composition from step (3).

100. A patch according to Claim 99, wherein the constituents of the elastomeric component comprise: about 5% to about 50% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million; and about 50% to about 95% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

101. A patch according to Claim 99, wherein the constituents of the elastomeric component comprise: about 15% to about 25% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 75% to about 85% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

102. A patch according to Claim 99, wherein the constituents of the elastomeric component comprise: about 20% by weight of a polyisobutylene with a viscosity average molecular weight between about 500,000 and about 2.5 million, and about 80% by weight of a polyisobutylene with a viscosity average molecular weight between about 40,000 and about 100,000.

103. A patch according to Claim 99, wherein the constituents of the elastomeric component comprise: about 20% by weight of a polyisobutylene with a viscosity average molecular weight about 1.25 million and about 80% by weight of a polyisobutylene with a viscosity average molecular weight about 53,000.

104. A patch according to Claim 99, wherein the constituents of the elastomeric component comprise: about 60% to 100% of a polyisobutylene with a viscosity average molecular weight of about 750,000 to about 1,500,000; and 0% to about 40% of a polyisobutylene with a viscosity average molecular weight of about 40,000 to about 100,000.

105. A patch according to Claim 99, wherein the constituents of the elastomeric component are selected from the group consisting of a polyisoprene with a molecular weight of about 500,000 to about 1,200,000, a polybutadiene with a molecular weight of about 100,000 to about 500,000, a mixture of two or more of said polyisoprenes, a mixture of two or more of said polybutadienes, and a mixture of one or more of said polyisoprenes and one or more of said polybutadienes.

106. A patch according to Claim 85, wherein the resin has an average particle size of between about 1 μ m and about 80 μ m.

107. A patch according to Claim 85, wherein the resin has an average particle size of between about 2 μ m and about 10 μ m.

108. A patch according to Claim 85, comprising about 20 to about 150 parts by weight of the elastomeric component based on 100 parts by weight of the resin.

109. A patch according to Claim 85, comprising about 25 to about 75 parts by weight of the elastomeric component based on 100 parts by weight of the resin.

110. A patch according to Claim 85, which contains less than about 4% water by weight based on the total weight of the resin.

111. A patch according to Claim 85, which contains less than about 2% water by weight based on the total weight of the resin.

112. A patch according to Claim 85, wherein the drug is one that exhibits systemic action.

113. A patch according to Claim 85, wherein the drug is a narcotic analgesic.

114. A patch according to Claim 85, wherein the drug is morphine or a pharmaceutically acceptable salt thereof.

115. A patch according to Claim 85, wherein the drug is selected from the group consisting of digoxin, heparin, hydromorphone, buprenorphine, theophylline, melatonin, and pharmaceutically acceptable salts thereof.

116. A patch according to Claim 85, wherein the resin is distributed substantially uniformly throughout the elastomeric component.

117. A patch according to Claim 85, wherein the resin is distributed throughout the elastomeric component in a suitable gradient.

118. A patch according to Claim 85, wherein the drug is distributed substantially uniformly throughout the elastomeric component.

119. A patch according to Claim 85, wherein the drug is distributed throughout the elastomeric component in a suitable gradient.

120. A patch according to Claim 85, which exhibits a duration of adhesion of at least about 8 hours when tested according to Step 2 of the Test Method.

121. A patch according to Claim 85, which exhibits a duration of adhesion of at least about 12 hours when tested according to Step 2 of the Test Method.

122. A method of achieving and/or maintaining a therapeutically effective blood level of a drug in a mammal, which method comprises the steps of:

a) adhering a composition according to Claim 1 to a mucosal surface of a mammal; and

b) allowing the composition to remain adhered for a time sufficient to release drug such that a therapeutically effective blood level of drug is achieved and/or maintained.

123. A method of achieving and/or maintaining a therapeutically effective blood level of a drug in a mammal, which method comprises the steps of:

a) adhering a patch according to Claim 85 to a mucosal surface of a mammal; and

b) allowing the patch to remain adhered for a time sufficient to release drug such that a therapeutically effective blood level of drug is achieved and/or maintained.

124. A method of delivering a drug to a mucosal surface of a mammal or to the vicinity of a mucosal surface of a mammal to provide a therapeutic effect on or in the vicinity of the mucosal surface, which method comprises the steps of:

5

a) adhering a composition according to Claim 1 to the mucosal surface;

b) allowing the composition to remain adhered for a time sufficient to release the drug to the mucosal surface or to the vicinity of the mucosal surface to provide the desired therapeutic effect.

10

15

20

25

30

35

Abstract of the Disclosure

5 A bioadhesive composition that adheres
suitably to a mucosal surface and is capable of delivering
drugs in sustained fashion, and a patch comprising the
bioadhesive composition. Methods of using and processes
for preparing the bioadhesive composition are also
10 described.

15

20

25

30

35

COPY

Docket No. 43852USA4C

OATH, POWER OF ATTORNEY, AND PETITION

Being duly sworn, We, Matthew T. Scholz, Robert A. Scherrer, Nelda M. Marecki, Yen-Lane Chen and Joan K. Barkhaus, depose and say that: (1) our respective residences, citizenships, and mailing addresses are indicated below; (2) we have reviewed and understand the contents of our patent application including the claims, as amended by any amendment specifically referred to herein, which is identified as U.S. Patent Application Serial No. 07/607,863, November 1, 1990, and we verily believe that we are the original, first, and joint inventors or discoverers of the invention or discovery in

BIOADHESIVE COMPOSITION AND PATCH

described and claimed therein and for which a patent is sought; (3) this application in part discloses and claims subject matter disclosed in earlier filed pending application Serial No. 07/486,554, filed February 27, 1990 which in part discloses and claims subject matter disclosed in earlier filed pending application Serial No. 07/431,664 filed November 3, 1989;

(4) we acknowledge our duty to disclose to the Patent and Trademark Office information we are aware of which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a)*; (5) as to the subject matter of this application which is common to one or both of said earlier applications we do not know and do not believe that the same was ever known or used in the United States of America before our invention or discovery thereof or patented or described in any printed publication in any country before our invention or discovery thereof, or more than one year prior to said earlier application, or in public use or on sale in the United States of America more than one year prior to said earlier application; (6) said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States of America on an application filed by us or our legal representatives or assigns more than twelve months prior to said earlier application; and (7) no application for patent or inventor's certificate on said common subject matter has been filed by us or our legal representatives or assigns in any country foreign to the United States of America;

(8) As to the subject matter of this application which is not common to any of said earlier applications, we do not know and do not believe that the same was ever known or used in the United States of America before our invention or discovery thereof or patented or described in any printed publication in any country before our invention or discovery thereof, or more than one year prior to the date of this application, or in public use or on sale in the United States of America more than one year prior to the date of this application; (9) said non-common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by us or our legal representatives or assigns more than twelve months before the date of this application; (10) no application for patent or inventor's certificate on said non-common subject matter has been filed by us or our representatives or assigns in any country foreign to the United States of America; and (11) we acknowledge our duty to disclose to the Patent and Trademark Office material information as defined in Title 37, Code of Federal Regulations, §1.56(a)* which occurred between the filing date of said earlier application and the date of this application.

We hereby appoint Gary L. Griswold (Reg. No. 25,396), Walter N. Kirn (Reg. No. 21,196), Roger R. Tamte (Reg. No. 21,093), Warren R. Bovee (Reg. No. 26,434), John C. Barnes (Reg. No. 20,278), and Robert W. Sprague (Reg. No. 30,497) our attorneys with full powers (including the powers of appointment, substitution, and revocation) to prosecute this application and any division, continuation, continuation-in-part, reexamination, or reissue thereof, and to transact all business in the Patent and Trademark Office connected therewith; the mailing address and the telephone number of the above-mentioned attorneys are

*Title 37, Code of Federal Regulations, §1.56(a) is reproduced on the last page of this form
This form may be executed only when attached to the specification (including claims) as the last page thereof.
32-121090/24.24

Attention: Robert W. Sprague
3M Office of Patent Counsel
P.O. Box 33427
St. Paul, Minnesota 55133-3427
Telephone No. (612) 733-1500


Wherefore, we pray that Letters Patent be granted to us for the invention or discovery described and claimed in the attached specification and we hereby subscribe our names to the foregoing specification and claims, oath, power of attorney, and this petition, this 21st day of JANUARY, 1991.

Inventor: Matthew T. Scholz
Matthew T. Scholz
Residence: City of Woodbury, County of Washington, State of Minnesota
Citizenship: United States of America
Post Office: P.O. Box 33427
Address: St. Paul, Minnesota 55133-3427

STATE OF MINNESOTA }
COUNTY OF RAMSEY } SS.

Before me personally appeared Matthew T. Scholz, to me known to be the persons described in the above application for patent, who signed the foregoing instrument in my presence, and made oath before me to the allegations set forth therein as being under oath, on the day and year aforesaid.

(SEAL)



Diann L. Schneider


Wherefore, we pray that Letters Patent be granted to us for the invention or discovery described and claimed in the attached specification and we hereby subscribe our names to the foregoing specification and claims, oath, power of attorney, and this petition, this 21st day of January, 1991.

Inventor: Robert A. Scherrer
Robert A. Scherrer
Residence: City of White Bear Lake, County of Ramsey, State of Minnesota
Citizenship: United States of America
Post Office: P.O. Box 33427
Address: St. Paul, Minnesota 55133-3427

STATE OF MINNESOTA }
COUNTY OF RAMSEY } SS.

Before me personally appeared Robert A. Scherrer, to me known to be the persons described in the above application for patent, who signed the foregoing instrument in my presence, and made oath before me to the allegations set forth therein as being under oath, on the day and year aforesaid.

(SEAL)



Cheryl A. Saver


Wherefore, we pray that Letters Patent be granted to us for the invention or discovery described and claimed in the attached specification and we hereby subscribe our names to the foregoing specification and claims. oath, power of attorney, and this petition, this 18 day of January, 1991.

Inventor: Nelda M. Marecki
Nelda M. Marecki
Residence: Township of May, County of Washington, State of Minnesota
Citizenship: United States of America
Post Office: P.O. Box 33427
Address: St. Paul, Minnesota 55133-3427

STATE OF MINNESOTA }
COUNTY OF RAMSEY } SS.

Before me personally appeared Nelda M. Marecki, to me known to be the persons described in the above application for patent, who signed the foregoing instrument in my presence, and made oath before me to the allegations set forth therein as being under oath, on the day and year aforesaid.

(SEAL)



Susan M. Dacko


Wherefore, we pray that Letters Patent be granted to us for the invention or discovery described and claimed in the attached specification and we hereby subscribe our names to the foregoing specification and claims. oath, power of attorney, and this petition, this 24~~th~~ day of January, 1991.

Inventor: Yen-Lane Chen
Yen-Lane Chen
Residence: City of New Brighton, County of Ramsey, State of Minnesota
Citizenship: Taiwan
Post Office: P.O. Box 33427
Address: St. Paul, Minnesota 55133-3427

STATE OF MINNESOTA }
COUNTY OF RAMSEY } SS.

Before me personally appeared Yen-Lane Chen, to me known to be the persons described in the above application for patent, who signed the foregoing instrument in my presence, and made oath before me to the allegations set forth therein as being under oath, on the day and year aforesaid.

(SEAL)



Cheryl A. Saver


Wherefore, we pray that Letters Patent be granted to us for the invention or discovery described and claimed in the attached specification and we hereby subscribe our names to the foregoing specification and claims, oath, power of attorney, and this petition, this 24th day of JANUARY, 19 91.

Inventor: Joan K. Barkhaus
Residence: Joan K. Barkhaus
City of Minneapolis, County of
Hennepin, State of Minnesota
Citizenship: United States of America
Post Office: P.O. Box 33427
Address: St. Paul, Minnesota 55133-3427

STATE OF MINNESOTA }
COUNTY OF RAMSEY } SS.

Before me personally appeared Joan K. Barkhaus, to me known to be the persons described in the above application for patent, who signed the foregoing instrument in my presence, and made oath before me to the allegations set forth therein as being under oath, on the day and year aforesaid.

(SEAL)



Diann L. Schneider

§1.56 Duty of disclosure; fraud; striking or rejection of application.

(a) A duty of candor and good faith toward the Patent and Trademark Office rests on the inventor, on each attorney or agent who prepares or prosecutes the application and on every other individual who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application. All such individuals have a duty to disclose to the Office information they are aware of which is material to the examination of the application. Such information is material where there is substantial likelihood that a reasonable examiner would consider it important in deciding whether to allow the application to issue as a patent. The duty is commensurate with the degree of involvement in the preparation or prosecution of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of:</p> <p>MATTHEW T. SCHOLZ, ROBERT A. SCHERRER, NELDA M. MARECKI, YEN-LANE CHEN AND JOAN K. BARKHAUS</p> <p>Serial No.: 08/510,046</p> <p>Filed: May 31, 1995</p> <p>For: BIOADHESIVE COMPOSITION AND PATCH</p> <p>Art Unit: 1502</p> <p>Examiner: P. Kulkosky</p>	<p>I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date noted below my signature.</p> <p>_____</p> <p>Date: _____</p>
---	---

Assistant Commissioner for Patents
Washington, D.C. 20231

ASSOCIATE POWER OF ATTORNEY

The undersigned hereby grants Charles L. Gholz, Registration No. 26,395, Oblon, Spivak, McClelland, Maier & Neustadt, P.C., Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202, Phone: (703) 412-6486, an Associate Power of Attorney to prosecute the above-identified application and continuations/divisionals thereof.

April 23, 1997
Date

Respectfully submitted,
Walter N. Kim
Walter N. Kim
Registration No. 21,196

3M Office of Intellectual Property Counsel
P.O. Box 33427
St. Paul, Minnesota 55133-3427
Telephone: (612) 733-1523
Facsimile: (612) 736-3833

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of:</p> <p>MATTHEW T. SCHOLZ, ROBERT A. SCHERRER, NELDA M. MARECKI, YEN-LANE CHEN AND JOAN K. BARKHAUS</p> <p>Serial No.: 08/510,046</p> <p>Filed: May 31, 1995</p> <p>For: BIOADHESIVE COMPOSITION AND PATCH</p> <p>Art Unit: 1502</p> <p>Examiner: P. Kulkosky</p>	<p>I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date noted below my signature.</p> <p>_____</p> <p>Date: _____</p>
---	---

Assistant Commissioner for Patents
Washington, D.C. 20231

ASSOCIATE POWER OF ATTORNEY

The undersigned hereby grants Alton D. Rollins, Registration No. 34,083, Oblon, Spivak, McClelland, Maier & Neustadt, P.C., Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202, Phone: (703) 412-6486, an Associate Power of Attorney to prosecute the above-identified application and continuations/divisionals thereof.

Respectfully submitted,

April 28, 1997
Date

Walter N. Kirm
Walter N. Kirm
Registration No. 21,196

3M Office of Intellectual Property Counsel
P.O. Box 33427
St. Paul, Minnesota 55133-3427
Telephone: (612) 733-1523
Facsimile: (612) 736-3833



1998-028-25DIV

IN RE APPLICATION OF

MATTHEW T. SCHOLZ,
ROBERT A. SCHERRER,
NELDA M. MARECKI
YEN-LANE CHEN AND
JOAN K. BARKHAUS

:

:GROUP ART UNIT: 1502
: (anticipated)

:

:

:

SERIAL NO: Divisional of
08/510,046

:EXAMINER: P. KULKOSKY
(anticipated)

FILED: Herewith

:

FOR: BIOADHESIVE COMPOSITION
AND PATCH

REQUEST FOR EXPEDITED PROSECUTION

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

The examiner is respectfully reminded that 37 CFR
1.607(b) provides in relevant part that:

When an applicant seeks an interference with a
patent, examination of the application... shall be
conducted with special dispatch within the Patent
and Trademark Office.

Respectfully submitted,

Alton D. Rollins

Charles L. Gholz
Registration No. 26,395
Alton D. Rollins
Registration No. 34,083
OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Fourth Floor
1755 Jefferson Davis Highway
Arlington, Virginia 22202
(703) 413-3000

1998-028-25 DIV

IN RE APPLICATION OF

MATTHEW T. SCHOLZ,
ROBERT A. SCHERRER,
NELDA M. MARECKI
YEN-LANE CHEN AND
JOAN K. BARKHAUS

:
:
:
:
:
:

GROUP ART UNIT: 1502
(anticipated)

SERIAL NO: divisional of
 08/510,046

:
:

EXAMINER: P. KULKOSKY
(anticipated)

FILED: Herewith

:

FOR: BIOADHESIVE COMPOSITION
 AND PATCH

37 CFR 1.607 REQUEST FOR AN
INTERFERENCE WITH A PATENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

I. 37 CFR 1.607(a)(1)

The patent is U.S. patent No. 5,516,523 issued May 14, 1996 and naming Sonia J. Heiber, Charles D. Ebert, and Sirish C. Dave as inventors. The assignee at issue was TheraTech, Inc. of Salt Lake City, Utah.

II. 37 CFR 1.607(a)(2)

Applicants propose the following count, which is in the format approved by the Commissioner in Orikasa v. Oonishi, 10 USPQ2d 1999, 2003 (Comm'r 1990), and Davis v. Uke, 27 USPQ2d 1180, 1188 (Comm'r 1993):

Claim 1 in the Heiber et al. patent

OR

Claims 125, 132, or 139 in the Scholz et al. patent application.

An extra copy of the proposed count is submitted herewith for the examiner's use in filling out the form PTO-850. In addition, as explained in section IX of this request, a proposed form PTO-850 is submitted herewith for the examiner's convenience.

III. 37 CFR 1.607(a)(3)

All 24 claims in the Heiber et al. patent correspond to the proposed count. Indeed, the proposed count includes all of the independent claims in that patent.

IV. 37 CFR 1.607(a)(4)

Claims 125-144 presented in the 37 CFR 1.607(a)(4) amendment submitted herewith correspond to the proposed count. Indeed, the proposed count includes all of the independent claims in that group of claims.

While dependent claims 126-131, 133-138, and 140-144 do not correspond exactly to the proposed count, the applicants do not currently argue that any of those claims is drawn to a separate patentable invention within the meaning of 37 CFR 1.601(n).

V. 37 CFR 1.607(a)(5)

The terms of the application claims identified as corresponding to the proposed count and not previously in the

application can be applied to the disclosure of the application as follows:

Terms of the Claims

Application to the
Disclosure of the
Application

125. A method for mucosally administering a macromolecular drug to the oral cavity comprising

Page 4 lines 13-22 and 34-37.

applying to the oral cavity mucosa a system comprising

Page 4 lines 34-37 and page 5 lines 3-6.

an inner drug/

Page 3 lines 24-25.

enhancer/

Page 14 lines 14-31.

polymer

Page 3 lines 14-20

layer having one surface adapted to contact the mucosal tissue of the oral cavity and adhere thereto when wet and

Page 3 line 25 - page 4 line 6 and page 4 lines 27-28.

an opposing surface in contact with and adhering to an overlying inert layer,

Page 4 lines 3-5

said inner layer containing an effective amount of a bile salt enhancer,

Page 14 lines 14-30.

from about 29 to 80% by weight of a hydrophilic polymer,

Page 3 lines 21-23. (100 parts of hydrophilic resin to 20-250 parts of hydrophobic resin.)

and an effective amount of a macromolecular drug.

Page 3 lines 24-25 and page 12 line 5 to page 13 line 21. Heparin (page 13 line 19); insulin (page 13 lines 5-6); and peptides and proteins (page 14 lines 19-

21) are macromolecular drugs.

126. A method according to claim 125 wherein said bile salt enhancer is selected from the group consisting of sodium glycocholate, sodium taurocholate, and sodium tauro-24, 25-dihydrofusidate.

Page 14 lines 14-31.

127. A method according to claim 126 wherein said macromolecular drug is a member selected from the group consisting of polysaccharides, polypeptides, and proteins.

Page 14 lines 19-21; page 13 lines 3-6; insulin (page 13 line 5); and heparin (page 13 lines 10 and 19), a polysaccharide.

128. A method according to claim 127, wherein said hydrophilic polymer is a member selected from the group consisting of acrylic acid polymers, maleic acid polymers, itaconic acid polymers, citraconic acid polymers, methacrylic acid polymers;

Page 5 line 10 - page 12 line 8. Applicants' preferred hydrophilic polymer, Carbopol® 934 is well recognized as being a hydrophilic polymer. See Kirk-Othmer, Encyclopedia of Chemical Technology, Vol. 20 pp. 216-219. (John Wiley & Sons, 1982) (Attachment A).

copolymers of a member selected from the group consisting of acrylic acid and methacrylic acid with a member selected from the group consisting of methyl vinyl ether and lower alkyl methacrylates;

Page 5 lines 10-23

and acrylic acid polymers cross-linked with a polyalkenyl ether selected

Page 5 line 24 - page 6 line 8.
line 8.

from the group consisting of
an allyl ether of sucrose
and

an allyl ether of
pentaerythritol.

129. A method
according to claim 128
wherein the macromolecular
drug is a polysaccharide.

Page 13 lines 19-21.
Heparin is a macromolecular
polysaccharide. See claims
8 and 9 of the '523 patent.

130. A method
according to claim 129
wherein the polysaccharide
is heparin.

Page 13 lines 19-21.

131. A method
according to claim 128 in
the form of a film patch
wherein said inert layer is
a polymer which is
nonadhesive to mucosal
tissues and

Page 18 lines 9-34.

is substantially impermeable
to the bile salt enhancer or
the drug.

132. A method for
mucosally administering a
macromolecular drug to the
oral cavity comprising

Page 4 lines 13-22 and 34-
37.

applying to an oral cavity
mucosa a system comprising

Page 4 lines 34-37 and page
5 lines 3-6.

an inner drug/
enhancer/
polymer/

Page 3 lines 24-25.
Page 14 lines 14-31.
Page 3 lines 14-20.

layer having one
surface adapted to contact

Page 3 line 25 - page 4 line
6 and page 4 lines 27-28.

the mucosal tissue of the oral cavity and adhere thereto when wet and an opposing surface in contact with and adhering to an overlying inert layer

said inner layer containing from 0% to an effective amount by weight of a bile salt enhancer,

about 29 to 80% by weight of a hydrophilic polymer, and

an effective amount of a macromolecular drug.

133. A method according to claim 132 wherein the bile salt enhancer is sodium taurocholate.

134. A method according to claim 133 wherein said macromolecular drug is a member selected from the group consisting of polysaccharides, polypeptides, and proteins.

135. A method according to claim 134 wherein said hydrophilic polymer is a member selected from the group consisting of acrylic acid polymers, methacrylic acid polymers,

Page 14 lines 14-30.

Page 3 lines 21-23 (100 parts hydrophilic polymer to 20-250 parts hydrophobic polymer).

Page 3 lines 24-25 and page 12 line 5 to page 13 line 21.

Page 14 lines 14-21.

Page 14 lines 19-21; page 13 lines 3-6; and insulin and heparin.

Page 5 line 10 - page 12 line 8. Applicants' preferred hydrophilic polymer, Carbopol® 934 is well recognized as a hydrophilic polymer. See Attachment A.

copolymers of acrylic acid
with a member selected from
the group consisting of
methyl vinyl ether and lower
alkyl methacrylates,

methacrylic acid copolymers
with a member selected from
the group consisting of
methyl vinyl ether and lower
alkyl methacrylates,

Page 5 lines 17-22.

and polymers of acrylic acid
cross-linked with a
polyalkenyl polyether.

Page 5 lines 24-34

136. A method
according to claim 135
wherein the macromolecular
drug is a polysaccharide.

Page 13 lines 19-21.

137. A method
according to claim 136
wherein the polysaccharide
is heparin.

Page 13 lines 19-21.

138. A method
according to claim 135 in
the form of a film patch
wherein said inert layer is
a polymer which is
nonadhesive to mucosal
tissues and is substantially
impermeable to the bile salt
enhancer or drug.

Page 18 lines 9-34.

139. A method for
mucosally administering a
macromolecular drug to the
oral cavity comprising

Page 4 lines 13-22 and 34-
37.

applying to an oral cavity
mucosa a system comprising

Page 4 lines 34-37 and page
5 lines 3-6.

an inner drug/

Page 3 lines 24-25.

polymer

Page 3 lines 14-20

layer having one surface adapted to contact the mucosal tissue of the oral cavity and adhere thereto when wet and an opposing surface in contact with and adhering to an overlying inert layer,

Page 3 line 25 - page 4 lines 6 and 27-28.

said inner layer containing from about 29 to about 80% of weight of a hydrophilic polymer

Page 3 lines 21-23.

and an effective amount of a macromolecular drug.

Page 3 lines 24-25 and page 12 line 5 to page 13 line 21. Heparin (page 13 line 19); insulin (page 13 lines 5-6); and peptides and proteins (page 14 lines 19-21) are macromolecular drugs.

140. A method according to claim 139 wherein the macromolecular drug is a member selected from the group consisting of polysaccharides, peptides, and proteins.

Page 14 lines 19-21; page 13 lines 3-6; page 13 line 5 (insulin); and page 13 lines 10 and 19 (heparin).

141. A method according to claim 140 wherein said hydrophilic polymer is a member selected from the group consisting of polyacrylic acid, polymethacrylic acid, copolymers of acrylic acid with a member selected from the group consisting of methyl vinyl ether and lower alkyl methacrylates,

Page 5 line 10 - page 12 line 8.

copolymers of methacrylic acid with a member selected from the group consisting of methyl vinyl ether and alkyl methacrylates,

and polymers of acrylic acid cross-linked with a polyalkenyl polyether.

142. A method according to claim 141 wherein the macromolecular drug is a polysaccharide.

Page 13 lines 10 and 19 (heparin).

143. A method according to claim 142 wherein the polysaccharide is heparin.

Page 13 lines 10 and 19.

144. A method according to claim 139 wherein the macromolecular drug is heparin and

Page 13 lines 10 and 19.

the hydrophilic polymer is a linear polyacrylic acid resin cross-linked with a member selected from the group consisting of an allyl ether of sucrose and an allyl ether of pentaerythritol.

Page 5 line 24 - page 6 line 8.

VI. 37 CFR 1.607(a)(6)

37 CFR 1.607(a)(6) is irrelevant since this request and the accompanying 37 CFR 1.607(a)(4) amendment are being

submitted prior to one year from the date on which the Heibert et al. patent was granted.

VII. REQUEST FOR THE BENEFIT OF THE FILING DATE
OF APPLICANTS' PRIORITY APPLICATIONS

Applicants claim priority under 35 USC 120 based upon application SN 08/510,046 filed on May 31, 1995, 07/842,222, filed on February 26, 1992, 07/607,863 filed on November 01, 1990, 07/486,554 filed on February 27, 1990, and 07/431,664 filed on November 03, 1989. Applicants are entitled to the benefit of the filing dates of their earlier applications for interference purposes if the count reads on at least one adequately disclosed embodiment in the earlier application.¹ Assuming that the examiner recommends to the board applicants' proposed count, applicants clearly meet that standard. That this is so is demonstrated in the following table, which reads the terms of the count on their earlier applications.

<u>Terms of the Count</u>	<u>Application of the Terms of the Count to the Disclosure of the 510,046 Application</u>
A method of mucosally administering a macromolecular drug to the oral cavity comprising	Page 4 lines 13-22 and 34-37.
applying to an oral cavity mucosa a system comprising an inner drug/	Page 4 lines 34-37 and page 5 lines 3-6. Page 3 lines 24-25.

¹Weil v. Fritz, 572 F.2d 856, 865-66 n. 16, 196 USPQ 600, 608 n. 16 (CCPA 1978).

enhancer/

Page 14 lines 14-31.

polymer/

Page 3 lines 14-31.

layer having one surface in contact with and adhering to the mucosal tissue of the oral cavity and an opposing surface in contact with and adhering to an overlying inert layer

Page 3 line 25 - page 4 lines 6, 27, and 28.

said inner layer containing from about two to sixty percent by weight of a bile salt enhancer,

Page 14 lines 14-30.

five to sixty five percent by weight of a hydrophilic polymer and

Page 3 lines 21-23 (100 parts of hydrophilic polymer to 20-250 parts of hydrophobic polymer).

an effective amount of a macromolecular drug having a molecular weight of at least 500 daltons.

Page 3 lines 24-25 and page 12 line 5 to page 13 line 21. Heparin (page 13 line 19); insulin (page 13 lines 5-6); and peptides and proteins (page 14 lines 19-21) are macromolecular drugs.

or

A method for mucosally administering a macromolecular drug to the oral cavity comprising

Page 4 lines 13-22 and 34-37.

applying to the oral cavity mucosa a system comprising

Page 4 lines 34-37 and page 5 lines 3-6.

an inner drug/

Page 3 lines 24-25.

enhancer/

Page 14 lines 14-31.

polymer

Page 3 lines 14-20

layer having one surface adapted to contact the mucosal tissue of the oral cavity and adhere thereto when wet and

Page 3 line 25 - page 4 line 6 and page 4 lines 27-28.

an opposing surface in contact with and adhering to an overlying inert layer,

Page 4 lines 3-5

said inner layer containing an effective amount of bile salt enhancer,

Page 14 lines 14-30.

from about 29 to 80% by weight of a hydrophilic polymer

Page 3 lines 21-23. (100 parts of hydrophilic resin to 20-250 parts of hydrophobic resin).

and an effective amount of a macromolecular drug.

Page 3 lines 24-25 and page 12 line 5 to page 13 line 21. Heparin (page 13 line 19); insulin (page 13 lines 5-6); and peptides and proteins (page 14 lines 19-21) are macromolecular drugs.

or

A method for mucosally administering a macromolecular drug to the oral cavity comprising

Page 4 lines 13-22 and 34-37.

applying to an oral cavity mucosa a system comprising

Page 4 lines 34-37 and page 5 lines 3-6.

an inner drug/
enhancer/
polymer/

Page 3 lines 24-25.
Page 14 lines 14-31.
Page 3 lines 14-20.

layer having one surface adapted to contact the mucosal tissue of the oral cavity and adhere thereto when wet and an opposing surface in contact with and adhering to an overlying inert layer

Page 3 line 25 - page 4 line 6 and page 4 lines 27-28.

Page 14 lines 14-30

said inner layer
containing from 0% to an
effective amount by weight
of a bile salt enhancer,

about 29 to 80% by weight of
a hydrophilic polymer, and

Page 3 lines 21-23 (100
parts hydrophilic polymer to
20-250 parts hydrophobic
polymer).

an effective amount of
a macromolecular drug.

Page 3 lines 24-25 and page
12 line 5 to page 13 line
21.

139. A method for
mucosally administering a
macromolecular drug to the
oral cavity comprising

Page 4 lines 13-22 and 34-
37.

applying to an oral cavity
mucosa a system comprising

Page 4 lines 34-37 and page
5 lines 3-6.

an inner drug/

Page 3 lines 24-25.

polymer

Page 3 lines 14-20

layer having one surface
adapted to contact the
mucosal tissue of the oral
cavity and adhere thereto
when wet and an opposing
surface in contact with and
adhering to an overlying
inert layer,

Page 3 line 25 - page 4
lines 6 and 27-28.

said inner layer
containing from about 29 to
about 80% of weight of a
hydrophilic polymer

Page 3 lines 21-23.

and an effective amount of a
macromolecular drug.

Page 3 lines 24-25 and page
12 line 5 to page 13 line
21. Heparin (page 13 line
19); insulin (page 13 lines
5-6); and peptides and
proteins (page 14 lines 19-
21) are macromolecular
drugs.

Since applicants' application is a straight continuation or division of the disclosures of application serial Nos. 08/510,046, 07/842,222, and 07/607,863, the disclosures of applicants' application is identical to the disclosures of those applications.

Application S.N. 431,664 discloses the hydrophilic polymer limitations of each of the alternative portions of the count at page 1 lines 2-28; the penetration enhancers at page 12 line 27 to page 13 line 7, particularly page 13 lines 2-5; and the macromolecular drug at page 10 line 20 to page 12 line 30 (including heparin, insulin, and human or animal growth hormones).

Example 13 at pages 26-27 of the 431,664 application describes patches containing 45% Carbopol® 910, a hydrophilic polymer, and 15% morphine sulfate, a macromolecular drug (molecular weight 669 daltons).

Application S.N. 486,554 carries forward the above disclosures from the 431,664 application at page 3 lines 8-34, page 5 line 4 to page 6 line 14, page 11 line 1 to page 12 line 33, page 13 lines 6-23, and Example 13 at pages 25-26.


VIII. 37 CFR 1.608

37 CFR 1.608 is irrelevant since the effective filing date of this application precedes the effective filing date of the Heider et al. patent.

IX. SUBMISSION OF PROPOSED FORM PTO-850

Submitted herewith for the convenience of the examiner is
a proposed form PTO-850.

Respectfully submitted,


Charles L. Gholz
Registration No. 26,395
Alton D. Rollins
Registration No. 34,083
OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Fourth Floor
1755 Jefferson Davis Highway
Arlington, Virginia 22202
Tel: (703) 413-3000
Fax: (703) 413-2220

I:\CLG\19980028\37cfr1607.Request.wpd

INTERFERENCE-INITIAL MEMORANDUM

EXAMINERS INSTRUCTIONS - This form need not be typewritten. Complete the items below and forward to the Group Clerk with all files including those benefit of which has been accorded. The parties need not be listed in any specific order. Use a separate form for each count.

(See MPEP 2309.02)

BOARD OF PATENT APPEALS AND INTERFERENCES: An interference is found to exist between the following cases:

This is count 1 of 1 count(s)

1. NAME	SERIAL NO.	FILING DATE	PATENT NO., IF ANY
Heiber et al.	243,415	May 16, 1994	5,516,523

The claims of this party which correspond to this count are:
1-24

The claims of this party which do not correspond to this count are:
NONE

*Accorded benefit of:

COUNTRY	SERIAL NO.	FILING DATE	PATENT NO., IF ANY
USA	027,508	February 22, 1993	5,346,701

2. NAME	SERIAL NO.	FILING DATE	PATENT NO., IF ANY
Scholz et al.	Not yet assigned	May 14, 1997	NONE

The claims of this party which correspond to this count are:
125-144

The claims of this party which do not correspond to this count are:
NONE

*Accorded benefit of:

COUNTRY	SERIAL NO.	FILING DATE	PATENT NO., IF ANY
USA	510,046	May 31, 1995	
USA	842,222	February 26, 1992	
USA	607,863	November 01, 1990	
USA	486,554	February 27, 1990	
USA	431,664	November 03, 1989	

3. NAME	SERIAL NO.	FILING DATE	PATENT NO., IF ANY

The claims of this party which correspond to this count are:

The claims of this party which do not correspond to this count are:

*Accorded benefit of:

COUNTRY	SERIAL NO.	FILING DATE	PATENT NO., IF ANY

If a claim of any party is exactly the same as this count, it should be circled above. If not, type the count in this space (attach additional sheet if necessary):

SEE ATTACHED SHEET

*The serial number and filing date of each application the benefit of which is intended to be accorded must be listed. It is not sufficient to merely list the earliest application necessary for continuity.

DATE	PRIMARY EXAMINER	TELEPHONE NO.	ART UNIT
NOTE: FORWARD ALL FILES INCLUDING THOSE BENEFIT OF WHICH IS BEING ACCORDED.		GROUP DIRECTOR SIGNATURE (if required)	

CLAIM 1 OF THE COUNT

Claim 1 in the Heiber et al. patent

OR

Claims 125, 132, or 139 in the Scholz et al. patent application.

Claim 1 of the Hieber et al. patent consists of the following:

A method of mucosally administering a macromolecular drug to the oral cavity comprising applying to an oral cavity mucosa a system comprising an inner drug/enhancer/polymer/layer having one surface in contact with and adhering to the mucosal tissue of the oral cavity and an opposing surface in contact with and adhering to an overlying inert layer said inner layer containing from about two to sixty percent by weight of a bile salt enhancer, five to sixty five percent by weight of a hydrophilic polymer and an effective amount of a macromolecular drug having a molecular weight of at least 500 daltons.

Claims 125, 132, or 139 in the Scholz et al. patent application consist of the following:

125. A method for mucosally administering a macromolecular drug to the oral cavity comprising applying to the oral cavity mucosa a system comprising an inner drug/enhancer/polymer layer having one surface adapted to contact the mucosal tissue of the oral cavity and adhere

thereto when wet and an opposing surface in contact with and adhering to an overlying inert layer, said inner layer containing an effective amount of a bile salt enhancer, from about 29 to 80% by weight of a hydrophilic polymer, and an effective amount of a macromolecular drug.

132. A method for mucosally administering a macromolecular drug to the oral cavity comprising applying to an oral cavity mucosa a system comprising an inner drug/enhancer/polymer/layer having one surface adapted to contact the mucosal tissue of the oral cavity and adhere thereto when wet and an opposing surface in contact with and adhering to an overlying inert layer said inner layer containing from 0% to an effective amount by weight of a bile salt enhancer, about 29 to 80% by weight of a hydrophilic polymer, and an effective amount of a macromolecular drug.

139. A method for mucosally administering a macromolecular drug to the oral cavity comprising applying to an oral cavity mucosa a system comprising an inner drug/polymer layer having one surface adapted to contact the mucosal tissue of the oral cavity and adhere thereto when wet and an opposing surface in contact with and adhering to an overlying inert layer, said inner layer containing from about 29 to about 80% of weight of a hydrophilic polymer and an effective amount of a macromolecular drug.